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i) Introduction 
Advanced or locally advanced malignant conditions of the pelvis and/or abdomen can cause ureteric obstruction and 
associated impaired renal function . This obstruction can be managed by performing PCN tube insertion with or 
without antegrade double J - stent insertion [4]. 
Having PCN tubes in situ is associated with prolonged hospital stay which affects quality of life [4].The available 
literature reports clearly on the morbidity associated with PCN, as well as the immediate improvement in renal 
function post-PCN [1; 2; 3; 4; 6]. 
Some studies found that patients spend between 23% and 40% of their mean survival time in hospital due to 
complications associated with nephrostomy tubes [l]. Median survival in a study of 49 patients post percutaneous 
catheter was 174 days (14-602) [1]. Another study of 211 patients showed a median survival of 5.05 months (95% Cl = 
3.87-7.11; range 2 - 963 days) [3]. In another big study of 208 patients, the median survival was 144 days (0-1084), 
with 44 (21.2%) patients dying during hospitalisation (4].ln a smaller series of 32 patients, it was reported that each 
patient spent a mean of 29 days (range, 1-82 days) in hospital from the time of PCN placement until death or the end 
of the study period . This represented 33.3% of the median survival time (87days) in their study [5]. Most studies 
report combined major and minor complication rates for PCN placement of 10%, with a mortality rate of between 
0.05% and 0.3% [3]. Reported complications related to PCN are pyelonephritis (22.7%), hospital readmission (17.3%), 
dislodgment of the nephrostomy catheter requiring replacement (9.3%), haematuria (4%), blood transfusion (1.3%), 
and retroperitoneal haematoma (0.7%) [4]. 
Mean serum creatinine levels improved from 280umol/L to 150umol/L, post diversion in a large study of 208 patients 
(4]. In a smaller study of only 22 patients, mean serum creatinine improved from 516 umol/L (range 239-1019) pre-
PCN to 168 umol/L (range 85-265) post-PCN (p<0.0001]. It took an average of 17 days (range 3-78) to reach the nadir 
creatinine concentration [6]. There is limited data on the trend in renal function following the expected initial 
improvement post-PCN. One South African study looked at renal function as measured by serum creatinine pre-PCN, 
day3 post-PCN, day7 post-PCN and then serum creatinine >7days post-PCN. 
It is well known that urinary tract infection (UTI) is a risk factor for developing acute kidney injury. A study by Hsiao et 
al (7] investigated 790 patients who were admitted for UTI in a tertiary hospital in Taiwan. Of these patients, 12.3% 
(n=97) developed acute kidney injury, with 0.5% (n=4) of patients necessitating dialysis. 
The decision if a patient needs PCN can be difficult. Various prognostication models [1; 3; 4] have been described to 
assist the clinician and patient with the decision making process. None of these prognostication models has long-term 
renal function response or UTls post-PCN as factors affecting survival. 
As our primary objective, we described the response in renal function following PCN for obstructive uropathy due to 
abdominal/pelvic malignant conditions at our institution. We hypothesized that UTI post PCN is associated with poor 
response in renal function and therefor investigated the role of UTls in the response in renal function post-PCN. 
Demographic data were also collected and investigated to determine the association with renal function response 
post-PCN. 
5 
ii) Literature review 
Pubmed and Google searches were done looking for renal function and urinary tract infections in patients who had 
percutaneous nephrostomy for advanced pelvic and/or abdominal malignancy. 
9 journal articles and 1 poster presentation were identified to be of help in preparing our research manuscript. 
Herewith a summary of the articles used and the impact it had in our study: 
1) Prognostic factors in malignant ureteric obstruction 
BJ U I N TE R NA TI O NA L 2009 / 1 0 4, 9 3 8 - 9 4 1 / 
Andrew Lienert, Andrew Ing and Stephen Mark 
Urology, Christchurch Hospital, Christchurch, New Zealand 
Researchers from Christchurch, New Zealand, had the objective to validate a model to stratify patients with 
obstructive nephropathy due to malignant ureteric obstruction, associated with a poor prognosis, into different 
prognostic groups. This was in response to a recent report (lshioka et al.), identifying low serum albumin, degree of 
hydronephrosis and number of events related to metastatic disease as prognostic indicators before palliative 
decompression. They also attempted to identify additional factors that might help to predict a patient's likely 
prognosis. 
A retrospective review of all patients who had a nephrostomy tube inserted for malignant ureteric obstruction was 
done. 49 Patients fulfilled the inclusion criteria. The median age was 71 years and the median survival was 174 days. 
The demographic breakdown of their cohort showed 45% being female and 55% being male. The laterality of the PCN 
showed 22% having bilateral nephrostomies, while 78% only had unilateral PCN. The type of malignancy was recorded 
as follows: Prostate 15 (30%), Bladder 18 (36%), Colorectal 6 (12%), Cervical 3 (6%), Ovarian 2 (4%), Sarcoma 2 (4%), 
Pancreatic 2 (4%), and Breast 1 (2%). 
On univariate analysis, clinical factors associated with a shorter mean survival were low serum albumin level, low 
serum sodium and three or more events related to malignant dissemination. 
Patient age, gender, serum creatinine, serum potassium, serum calcium, or haemoglobin level were not useful 
prognostic indicators. Different degrees of hydronephrosis on renal ultrasonography before tube insertion were not 
associated with a difference in mean survival. 
Complications related to the nephrostomy tube were experienced by 39% of patients and 69 separate complications 
were recorded which required presentation at hospital. Complications included blockage of tube (31 events), 
displacement of tube (21 events), sepsis (11 events), haemorrhage (one event), and pain requiring inpatient 
management (five events). No patients died as a direct result of a complication of their tube. 
This model stratified patients into three groups with significantly different mean survival times. Patients in the 
favourable risk group (no risk factors) had a mean survival was 278 days, vs 173 days for the intermediate-risk group 
(one risk factor) and only 63 days for those in the high-risk group (two or three risk factors). 
The researchers were successful in validating the lshioka et al. model for prognostication post PCN for malignant 
ureteric obstruction. 
The researchers have not looked at renal function response in their series. Comparing bilateral vs unilateral PCN in the 
univariate analysis could have provided interesting results. We also planned to investigate is the incidence of urinary 
tract infection, which is lacking from this work. 
2) Impact of percutaneous nephrostomy in South African women with 
advanced cervical cancer and obstructive uropathy 
Southern African Journal of Gynaecological Oncology 2017; 9(1):6-10 
Matthys Cornelis van Aardt, Judith van Aardt and Arnold Mouton 
Obstetrics and Gynaecology, University of Pretoria, Pretoria, South Africa 
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This South African study did a retrospective audit of all patients with primary untreated cervical cancer with renal 
impairment secondary to obstructive uropathy. Serum Urea, creatinine and potassium were recorded for patients 
receiving PCN before insertion and after treatment. 
Fifty-four patients fulfilled the inclusion criteria for the study, however only a total of 28 patients received PCN. The 
mean age of the nephrostomy group was 48.4 years. Seventeen {31. 7%) patients were HIV infected and the majority 
(70.3%) were stage 111B cervical cancer. Of the patients who received PCN, 11 {39.3%) were classified as severe renal 
failure and 10 (35. 7%) as renal failure. 
The serum urea, creatinine and potassium levels were recorded before insertion of the PCN, on days three and day 
seven after insertion and after treatment or more than one week after nephrostomy insertion. In the PCN group, no 
mortalities were reported, 11.5% ended with worse renal function, 38.5% had unchanged renal function and 50% had 
improved renal function post-PCN. 
The researchers concluded that in patients with cervical cancer and obstructive uropathy, even if HIV positive, it is safe 
to offer PCN with minimal complications. An improvement in renal function was shown after PCN. PCN improved the 
number of patients qualifying for initiation and completion of treatment. 
This study is one of a very limited number of studies that looked at renal function at different time periods post-PCN. 
They looked at specific values on days 3 and 7 post-PCN. They recorded a further value beyond 7days. It is not clear 
how long after PCN these values were recorded. We aim to be clear on the timing of our best and worst values post-
PCN. Using eGFR and CKD-staging might help in categorising our cohort's renal functions more accurate. Although this 
is a South African study, our cohort will have a completely different demography as we are including all pelvic and 
abdominal malignant conditions causing ureteric obstruction. 
3} Clinical Factors Associated With a Short Survival Time After Percutaneous 
Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated 
Model 
Journal of Pain and Symptom Management 255 Vol. 51 No. 2 February2016 
Alia Alawneh, MD, Wa'el Tuqan, MD, Ayoub lnnabi, MD, Yanai AI-Nimer, MD, Ola Azzouqah, MD, Dalia 
Rimawi, SP, Ayat Taqash, SP, Maan Elkhatib, MD, and P _al Klepstad, MD, PhD King Hussein Cancer Center 
(A.A., W.T., A.I., D.R., A.T., M.E.), Amman, Jordan; Hamad Hospital (Y.A.-N.), Doha, Qatar; University of New 
Mexico (O.A.), Albuquerque, New Mexico, USA; and St. Olavs University Hospital (P.K.), Trondheim, Norway 
This paper from Jordan reported on an updated prognostic model to predict overall survival in cancer patients after 
receiving PCN. The primary objective was to assess survival of patients with malignant urinary obstruction after PCN 
tube insertion. The secondary objective was to identify factors associated with poor prognosis in this group of patients 
and externally validate an existing model. 
They did a retrospective analysis of 211 patients who had maiignant urinary obstruction and received PCN tube 
insertion. 52.1% received bilateral PCN insertion and 47.9% received unilateral PCN insertion. The most common 
malignancy in their sample was genitourinary cancer. 
The median survival was 5.05 months. On univariate analysis, the factors significantly associated with shorter survival 
were type of malignancy, bilateral hydronephrosis, serum albumin <3.5 mg/dL, presence of metastasis, ascites, and 
pleural effusion. They used serum albumin <3.5 mg/dL, pleural effusion, and bilateral hydronephrosis to stratify 
patients into four prognostic groups: zero risk factors (32 patients), one risk factor {85 patients), two risk factors (78 
patients), and three risk factors (16 patients). Median survival for each group was 17.6 months, 7.7 months, 2.2 
months, and 1.7 months, respectively. 
Serum creatinine prior to PCN was also recorded, with the median overall value of 2mg/dL (177umol/L). The group 
who had unilateral PCN had median of l.3mg/dL (115umol/L) and the patients who had bilateral PCN had median 
serum creatinine of 2.8mg/dL (248umol/L). 
They did not investigate renal function response post-PCN. This would have been interesting, as the group who had 
bilateral PCN had more to gain in terms of renal function recovery. The patients with bilateral nephrostomies did 
worse in terms of survival time, however. 
They concluded that their updated model can be used to identify patients with poor survival after PCN. 
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4) A prognostic model for survival after palliative urinary diversion for 
malignant ureteric obstruction: a prospective study of 208 patients 
BJU Int 2016; 117: 266-271 
Mauricio D. Cordeiro, Rafael F. Coelho, Daher C. Chade, Rodrigo R. Pessoa, Mateus S. Chaib, Jose R. 
Colombo-Junior, Jose Pontes-Junior, Giuliano B. Guglielmetti and Miguel Srougi 
Uro-Oncology Group, Urology Department, University of Sao Paulo Medical School and Institute of Cancer 
Estate of Sao Paulo, Sao Paulo, Brazil 
This is another study reporting on a prognostic model for survival post palliative urinary diversion for malignant 
ureteric obstruction. This time it was a prospective study of 208 patients that underwent palliative urinary diversion 
by ureteric stenting 58 patients) or percutaneous nephrostomy (150 patients) in two tertiary care university hospitals. 
Patients were followed-up for a minimum of 6 months. Factors related to poor prognosis were identified by Cox 
univariable and multivariable regression analyses, and a risk stratification model was created by Kaplan-Meier survival 
estimates at 1, 6 and 12 months. 
The median (range) survival was 144 days after urinary diversion. Overall survival did not differ by UD type. The 
number of events related to malignancy (~4) and Eastern Cooperative Oncology Group (ECOG) index (~2) were 
associated with short survival on multivariable analysis. These two risk factors were used to divide patients into three 
groups by survival type : favourable (no factors), intermediate (one factor) and unfavourable (two factors). The median 
survival at 1, 6, and 12 months was 94.4%, 57.3% and 44.9% in the favourable group; 78.0%, 36.3%, and 15.5% in the 
intermediate group; and 46.4%, 14.3%, and 7.1% in the unfavourable group. 
The mean serum creatinine level, before and after urinary diversion, was 0.28 and 0.15 mmol/L, (280 and 150 umol/L) 
respectively. No mention was made of the timing of the serum creatinine post diversion. 71 out of the 150 PCN 
patients (47%) had bilateral PCN, while 79 had unilateral PCN {53%}. 
Complications related to PCN were pyelonephritis in 22.7% of patients, hospital readmission in 17.3% of patients, 
dislodgment of the nephrostomy catheter requiring replacement in 9.3% of patients, haematuria in 4%of patients, 
blood transfusion in 1.3% of patients, and retroperitoneal haematoma in 0.7% of patients. 
The researchers investigated if age is an independent risk factor for survival, but could not be proven in their series. 
The investigators concluded that their stratification model may be useful to determine whether urinary diversion is 
indicated in malignant ureteric obstruction. This study highlights the improvement in renal function post-PCN, as well 
as the high incidence of UTI in this group of patients. 
5) The role of percutaneous nephrostomy in malignant ureteric obstruction 
Ann R Coll Surg Engl 2005; 87 
JR Wilson, GH Urwin, MJ Stower 
Department of Urology, York District Hospital, York, UK 
The aims of this UK study were to assess whether PCN placement in malignant ureteric obstruction provided any 
additional survival benefit or patient morbidity. 
They did a retrospective review of 32 patients with a mean age of 68.1 years (16 male, 16 female), who underwent 
PCN for malignant ureteric obstruction. Data collected for analysis included the site of primary malignancy, mode of 
presentation, improvement in renal function, median survival, conversion to internal ureteric stents and intervention-
related complications. 
The median survival following PCN insertion was 87 days and was unrelated to the patient's age and renal function. 
Those patients with primary underlying gynaecological malignancies appeared to survive almost 4 times as long as 
those with underlying primary bladder cancer. 
Twenty patients had bilateral PCN and 12 unilateral PCN placement. 
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Serum creatinine took a mean of 16.8 days to reach the lowest level post-PCN. Mean serum creatinine pre- and post-
PCN were 946.8 umol/L and 235.2umol/L respectively. No mention is made of what happens to renal function once 
the lowest serum creatinine levels had been reached. 
Almost 79% of patients were able to be discharged from hospital - each patient, however, being re-admitted back to 
hospital on average 1.6 times prior to their death through PCN or internal ureteric stent related events. 
Retrospective 'useful quality of life' was seen in less than half of the patient cohort. 
The conclusion was that in the presence of malignant ureteric obstruction, palliative PCN may be performed and is 
effective in improving renal function. Long-term survival is limited and should, therefore, be performed only when the 
views and wishes of the patient and carers are taken into account and if there is a definitive treatment plan available 
for the patient as quality of life can be suboptimal. 
6) Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic 
malignancy: have we got the balance right? 
Int Urol Nephrol {2013} 45:627-632 
Saumya Misra, Charles Coker and Jonathan Richen berg 
Department of Urology, Princess Royal Hospital, Brighton and Sussex University Hospitals NHS Trust 
This study assessed survival and complication rates post-PCN in patients with ureteric obstruction due to advanced 
pelvic malignancy. A retrospective case review of all patients who underwent PCN for ureteric obstruction due to 
pelvic malignancy in one calendar year was conducted to assess indication, survival time, length of stay post-
procedure and complications. 
They included 22 patients who had 36 nephrostomies performed on them. 50% of patients had bilateral 
nephrostomies. Prostate cancer was the commonest primary (55 %}. Renal failure was the commonest mode of 
presentation (56 %}. Mean serum creatinine for those with renal impairment (n = 16) was 516 umol/L, which 
improved to 168 umol/L post-PCN, with an average of 17 days to reach the lowest serum creatinine level. Two 
patients who had unilateral PCN had to be re-admitted due to worsening renal function post-PCN. One patient with 
bilateral PCN had to be admitted with worsening renal function. 
Median survival post-nephrostomy was 78 days, with the subset of bladder cancer patients having the poorest 
survival. Dislodgement of the nephrostomy tube was the most common complication which led to the greatest 
morbidity. Patients stayed for a median of 23 days in hospital, which amounted to 29 % of their remaining lifetime 
spent in hospital. 
The investigators concluded that PCN is effective in improving renal function, but it is also a procedure with associated 
morbidity and does not always prolong survival. The duration of improved renal function remains a void that our study 
aim to fill. 
7) Risk Factors for Development of Acute Kidney Injury in Patients with 
Urinary Tract Infection 
9 
PLOS ONE/ DOl:10.1371/journal.pone.0133835 July 27, 2015 
Chih-Yen Hsiao, Huang-Yu Yang, Meng-Chang Hsiao, Peir-Haur Hung, Ming- Cheng Wang, Department of 
Internal Medicine, Ditmanson Medical Foundation Chia-yi Christian Hospital, Chia-yi, Taiwan; Department 
of Hospital and Health Care administration; Chia-Nan University of Pharmacy and Science, Tainan, Taiwan; 
Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, 
Taoyuan, Taiwan; Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, 
United States of America; Department of Applied Life Science and Health, Chia-Nan University of Pharmacy 
and Science, Tainan, Taiwan; Division of Nephrology, Department of Internal Medicine, National Cheng 
Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Bloomberg 
School of Public Health, Johns Hopkins University, Baltimore, MD, 21205, United States of America 
This was a multinational trial that investigated the clinical characteristics and change of renal function to identify the 
risk factors for development of AKI in UTI patients. 
It was a retrospective study conducted in a tertiary referral centre, where a total of 790 UTI patients necessitating 
hospital admission were included for final analysis. 
Multivariate logistic regression analysis was performed to evaluate the risk factors for AKI in UTI patients. There were 
97 (12.3%) patients developing AKI during hospitalization. Multivariate logistic regression analysis showed that 
patients with older age, diabetes mellitus (DM), upper UTI, afebrile during hospitalization and lower baseline eGFR 
were associated with increased risk for development of AKI. 
Many of the patients requiring PCN for malignant ureteric obstruction have lower baseline eGFR, advanced age, and 
upper UTI. This will put our study population at a high risk to develop AKI if patient acquires UTI. 
8) Percutaneous nephrostomy versus indwelling ureteral stents in the 
management of extrinsic ureteral obstruction in advanced malignancies: 
Are there differences? 
UROLOGY 64: 895-899, 2004. 
JA HYEON KU, SANG WOOK LEE, HWANG GYUN JEON, HYEON HOE KIM, AND SEUNG-JUNE OH 
Department of Urology, Seoul National University College of Medicine; and Clinical Research Institute, Seoul 
National University Hospital, Seoul, Republic of Korea 
This group compared the complications and morbidities after placement of a PCN or an internal ureteral stent (IUS) in 
the management of malignant ureteral obstruction in patients with advanced malignancy. 
A retrospective analysis was performed on a total of 148 patients with a mean age of 57.3 years and with malignant 
ureteral obstruction, who underwent PCN (80 patients) or IUS (68 patients). 
The incidence of fever and acute pyelonephritis was expressed as the number of episodes per 100 person-days. They 
found the accumulated incidence of fever and acute pyelonephritis was not different in the two groups. The 
accumulated incidence and the incidence of febrile episodes in the IUS group was 10.3% and 0.0004/100 person-days; 
the corresponding values for the PCN group were 15.0% and 0.2154/100 person-days. The incidence of acute 
pyelonephritis in the IUS and PCN groups was 0.0002/100 person-days and 
0.0005/100 person-days, respectively. 
The difference in overall stent-related or catheter-related complications between the IUS and PCN groups was not 
statistically significant. 
They have demonstrated that morbidities after internal or external diversion were minimal in cases of malignant 
obstruction. However, patients scheduled to receive an IUS should be more carefully monitored for ongoing 
obstruction than patients scheduled for PCN tube placement. 
9) Percutaneous Nephrostomy Tube-related Infections 
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IDWeek Session: 143. Clinical: UT/, Friday, October 6, 2017 
Ha nine El Haddad. MD; George Viola, MD MPH; Ying Jiang, MS; lssam Raad, MD; Kenneth V. Rolston, MD 
and Ariel Szvalb, MD. Section of Infectious Diseases, Baylor College of Medicine, Houston, Texas, 
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD 
Anderson Cancer Center, Houston, Texas 
This research was presented as a poster at IDWeek 2017. They wanted to determine whether discordant antimicrobial 
coverage provided prior to PCN exchange was associated with a higher rate of recurrent infection compared with those 
who received concordant therapy. 
A retrospective review of 780 patients that had undergone initial PCN placement was done. They only included patients 
that had developed a definite PCN infection, subsequent PCN exchange, with a minimum 30 day post-PCN exchange 
follow up. PCN infection was defined as the presence of a positive urine culture (~104 cfu/ml) plus symptoms consistent 
with a urinary tract infection. Recurrence was defined as a new PCN infection with the isolation of the same organism 
to the initial episode. Antibiotics were defined as concordant if they had activity against all organisms' isolated based 
on antimicrobial susceptibilities. 
A total of 47 patients met the inclusion criteria. The median age of patients was 59, with 49% being male. The most 
common underlying tumors were urothelial (45%), cervical (17%) and prostate cancer (15%). The median time to onset 
of infection was 42 days. Infections were polymicrobial in 50% of the cases. The most common organisms encountered 
were Pseudomonas spp. (36%), Enterococcus spp. (23%) and Escherichia coli (18%). There were 12 (26%) recurrences 
occurring at a median time of 27 days. The provision of discordant antibiotics preceding PCN exchange was significantly 
associated with recurrence of infection (66.7% vs. 12.8%). 
Discordant antimicrobial therapy provided during PCN exchange, in the setting of a PCN infection is associated with a 
higher rate of relapse. Therefore, to decrease the high rate for PCN reinfection, they proposed that prior to PCN 
exchange secondary to infection, patients should be receiving concordant antimicrobial therapy. 
The timing of onset of UTI and the high rate of recurrent infection is of significance in our study. 
10) Nephrostomy insertion for patients with bilateral ureteric obstruction 
caused by prostate cancer 
The British Journal of Radiology, 82 (2009), 571-576 
J Nariculam, MBBS, MRCS, G Murphy, MBBS, MD, FRCS, C Jenner, RGN, N Sellars, MBBS, MRCP, FRCR, S 
Gwyther, MBBS, FRCS, FRCR, S G Gordon, FRCS and M J Swinn, BSc, MBBS, FRCS, MSc, MD, FRCS (UROL) 
1St Helie; Hospital, Carshalton, Surrey, 2Guy's Hospital, London, 3East Surrey Hospital, Redhill and 4Epsom 
and St Helier NHS Trust, Epsom, Surrey, UK 
This study aimed to identify whether bilateral PCN insertion confers any advantage over unilateral PCN insertion for 
patients with bilateral ureteric obstruction. 
In a cohort of 25 patients, 18 underwent bilateral and 7 underwent unilateral PCN insertion. The mean survival time 
following PCN was 7.5 months for all patients. The data suggest that the nadir serum creatinine after PCN insertion 
was similar, independent of whether one or two nephrostomies were inserted. The mean baseline creatinine !evel 
prior to PCN was 612 umol/L. Following PCN, the mean creatinine level of all patients fell to 187 umol/L, taking an 
average of 10 days to reach this nadir. Among patients who underwent either unilateral or bilateral PCN, no major 
differences in post-PCN creatinine levels were seen. 
There was also little difference in the serum creatinine levels at the time of death, suggesting that survival after PCN 
insertion is based on the aggressiveness of the prostate cancer as opposed to the number of nephrostomies inserted. 
This is an interesting study that might be of relevance to our study. Perhaps the response in renal function is different 
between different malignant conditions that have different degrees of aggressiveness. 
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iii) In Summary: 
It is clear from above literature that having PCN is associated with morbidity. This include infection, bleeding, blocked 
nephrostomy tubes and prolonged hospital stay. This leads to a large proportion of patients spending a significant 
time of their remaining survival time in hospital. 
Literature reports on the improved renal function post-PCN, but with the background of increased morbidity. 
Literature is scarce on what happens to renal function after initial improvement post-PCN. Only one study [2] looked 
at renal function trends in their cohort of cervix carcinoma patients. Renal functions were recorded beyond 7 days 
post-PCN. 50% of their patients ended up with the same or worse renal function post-PCN. The numbers in this study 
was small. At least one study [6] reported on three patients of their small cohort of 22 patients, returning with 
worsening renal failure post-PCN. 
Our study determined accurately what the renal function trends are post-PCN within a six-month follow-up. 
It is reported in literature that patients with PCN have a high incidence of UTI [8; 4]. 
It is also known that UTI is a risk factor for developing acute kidney injury, especially in the elderly with comorbidities 
[7]. 
To our knowledge, no available research investigated if the development of UTI post-PCN is associated with poor renal 
function response post-PCN in this specific study population (patients with PCN for malignant ureteric obstruction). 
We investigated the incidence of UTI in our study population and the association with poor renal function response. 
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b. Abstract 
Background and purpose 
Malignant conditions of the pelvis and/or abdomen can cause ureteric obstruction and associated impaired renal 
function, which can be managed by performing percutaneous nephrostomy (PCN) tube insertion. Nephrostomy tubes 
are associated with prolonged hospital stay which affects quality of life. 
The main objective of this study was to assess the changes in estimated glomerular filtration rate (eGFR) over the first 
six months following percutaneous nephrostomy for malignant ureteric obstruction. We also explored the role of UTls 
in the changes of eGFR following PCN. 
Materials and Methods 
We performed a retrospective folder review of patients who had PCN procedures at Groote Schuur Hospital for 
malignant obstructive uropathy from January 2015 to 31 December 2017. 
For each included patient, eGFR was recorded at baseline pre-PCN, and at its best and worst value in the first six 
months after PCN. The timing of baseline, best and worst values were also recorded. 
Other data collected included demographic data, type of malignancy, laterality of nephrostomy and presence of 
confirmed UTI at least one week post PCN. 
Results/main findings 
A total of 90 patients fulfilled our inclusion criteria. The most common cancers in men were bladder 59% (n=32), 
prostate 20% (n=ll), lymphoma 7% (n=4), and colorectal 4% (n=2). The most common cancers in women were cervix 
64% (n=23), bladder 19% (n=7), lymphoma 6% (n=2), colorectal 6% (n=2) and endometrial 6% (n=2). Men were of 
higher age, median (IQR), 60 (56, 67) years, compared to women, 48 (40, 67). 64% of patients (n=58) had bilateral PCN 
procedures (as opposed to a unilateral procedure). 52% (n=47) of patients developed at least one episode of UTI post 
PCN during the six-month observation period. 
Median (IQR) timepoint of pre-PCN eGFR measurement was 1.0 (2.0, O) day pre PCN. The best post-PCN eGFR 
measurement was 13.0 (6.0, 26.0) days post PCN. The worst post-PCN measurement was 33.5 (14.0, 92.5) days post 
PCN. 
Pre-PCN eGFR, median (IQR), was 9 (5, 26). Post-PCN eGFR improved to 48 (30, 75) before deteriorating to 23 (9, 44) 
within the six-month follow-up window. 
Compared to patients who do not develop UTI post-PCN, those who develop one or more post-PCN UTl(s} have a 6.15 
(95% Cl: 0.87, 11.43) unit lower eGFR at their worst eGFR measurement. 
There are also markedly fewer deteriorations in chronic kidney disease (CKD) stages between best and worst post-PCN 
interval in those without UTI (42%, 18/43), compared to those with at least one post-PCN UTI (72%, 34/47). 
Conclusions 
Our study confirmed a similar renal function trend post-PCN for malignant ureteric obstruction across different 
demographics. It is clear that although most patients' renal function initially improve post-PCN, the general trend for 
the majority of patients is to deteriorate towards pre-PCN eGFR and CKD stage values. 
Our data suggest that urinary tract infections play an important role in poor renal function response within six months 
post-PCN. Future studies should explore whether the development of UTI following PCN is an independent and 
modifiable risk factor for poor renal outcome. 
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c. Introduction 
Advanced or locally advanced malignant conditions of the pelvis and/or abdomen can cause ureteric obstruction and 
associated impaired renal function. This obstruction can be managed by performing PCN tube insertion with or 
without antegrade double J - stent insertion [4]. 
Having PCN tubes in situ is associated with prolonged hospital stay which affects quality of life [4]. 
The available literature reports clearly on the morbidity associated with PCN, as well as the immediate improvement 
in renal function post-PCN [1; 2; 3; 4; 6]. 
Some studies found that patients spend between 23% and 40% of their mean survival time in hospital due to 
complications associated with nephrostomy tubes [1]. Median survival in a study of 49 patients post percutaneous 
catheter was 174 days (14-602) [1]. Another study of 211 patients showed a median survival of 5.05 months (95% Cl = 
3.87-7.11; range 2 - 963 days) [3]. In another big study of 208 patients, the median survival was 144 days {0-1084), 
with 44 (21.2%) patients dying during hospitalisation [4]. 
In a smaller series of 32 patients, it was reported that each patient spent a mean of 29 days (range, 1-82 days) in 
hospital from the time of PCN placement until death or the end of the study period. This represented 33.3% of the 
median survival time {87days) in their study [SJ. 
Most studies report combined major and minor complication rates for PCN placement of 10%, with a mortality rate of 
between 0.05% and 0.3% [3]. Reported complications related to PCN are pyelonephritis (22.7%), hospital readmission 
(17.3%), dislodgment of the nephrostomy catheter requiring replacement (9.3%), haematuria (4%), blood transfusion 
(1.3%), and retroperitoneal haematoma (0.7%) [4]. 
Mean serum creatinine levels improved from 280umol/L to lS0umol/L, post diversion in a large study of 208 patients 
[4]. In a smaller study of only 22 patients, mean serum creatinine improved from 516 umol/L (range 239-1019) pre-
PCN to 168 umol/L (range 85-265) post-PCN [p<0.0001]. It took an average of 17 days (range 3-78) to reach the nadir 
creatinine concentration [6]. 
There is limited data on the trend in renal function following the expected initial improvement post-PCN. One South 
African study looked at renal function as measured by serum creatinine pre-PCN, day3 post-PCN, D7 post-PCN and 
then serum creatinine >7days post-PCN. 
It is well known that urinary tract infection (UTI) is a risk factor for developing acute kidney injury. A study by Hsiao et 
al [7] investigated 790 patients who were admitted for UTI in a tertiary hospital in Taiwan. Of these patients, 12.3% 
(n=97) developed acute kidney injury, with 0.5% (n=4) of patients necessitating dialysis. 
The decision if a patient needs PCN can be difficult. Various prognostication models [1; 3; 4] have been described to 
assist the clinician and patient with the decision making process. None of these prognostication models has long-term 
renal function response or UTls post-PCN as factors affecting survival. 
As our primary objective, we described the response in renal function following PCN for obstructive uropathy due to 
abdominal/pelvic malignant conditions at our institution. We hypothesized that UTI post PCN is associated with poor 
response in renal function and therefor investigated the role of UTls in the response in renal function post-PCN. 
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d. Methods 
i) Selection and Description of Participants 
All patients who had percutaneous nephrostomy for malignant ureteric obstruction done at Groote Schuur Hospital 
between 1 January 2015 and 31 December 2017 were included in the study. All malignant conditions were considered 
for inclusion. Patients had to be followed-up for at least one week post percutaneous nephrostomy. Each patient was 
followed up for a maximum period of six months post-PCN. 
Patients who had failed percutaneous nephrostomy and those who weren't followed up for at least one-week post 
intervention, were excluded. No children were included in this study. 
Approval for this study was obtained from the University of Cape Town, Department of Surgery Departmental 
Research Committee (Project 2018/094). 
Human research ethics committee approval was obtained from the University of Cape Town, Faculty of Health 
Sciences (HREC REF: 097/2019) 
ii) Technical Information 
We performed a retrospective folder review of all patients with complete records identified during the specified time 
period. Data were extracted from the hospital radiology system and the National Health Laboratory Services {NHLS) 
laboratory system. 
Renal function was recorded as per the chronic kidney disease {CKD) staging system, according to estimated 
Glomerular Filtration Rate (eGFR) values" eGFR was determined using the MDRD equation . The chronic kidney disease 
(CKD) staging system we used is as follows (according to eGFR values): Stagel has eGFR ~90ml/min, Stage2 has eGFR 
60-89ml/min, Stage3 has eGFR 30 - 59ml/min, Stage4 has eGFR 15 - 29ml/min and Stages has eGFR < 15ml/min (11]. 
CKD stages and eGFR pre-PCN were compared to the best CKD stage/eGFR post-PCN and worst CKD stage/eGFR within 
six months post-PCN. A poor response was defined as the worst CKD stage post-PCN the same or worse than the pre-
PCN CKD stage. A good response was defined as the worst CKD stage post-PCN better than pre-PCN CKD stage. 
Urinary tract infections (UTls) were diagnosed if a patient had a positive microscopy and culture more than seven days 
post-PCN. UTI was defined as a single organism cultured in affected urine with a bacteria colony count of >10 000 
CFU/ml. UT!s identified within seven days post-PCN were assumed to be related to pre-existing infected urine or 
colonisation and were not included. UTls documented more than seven days post-PCN were considered as a new 
infection. 
We collected data for six months post-PCN, as this represents the upper end of the range for median survival for our 
target population [4]. 
We collected the following data: 1) demographics, 2) type of malignancy, 3) laterality of the nephrostomy tube, 4) 
renal function and 5) UTls. 
Demographics collected included the patient's age and sex. We also documented the primary malignant condition 
that caused the obstructive uropathy and if the PCN tube was inserted unilateral or bilateral. 
We grouped CKD Stagel and 2 together, since the laboratory we used for this trial do not offer specific eGFR values at 
levels ~60ml/min. If a patient had an eGFR ~60ml/min, we classified him/her as at worst CKD stage 2 and recorded his 
eGFR to be 75ml/min (midway between CKD stages 1 and 2). 
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iii) Statistics 
Continuous and interval data were described in terms of mean (standard deviation) or median (interquartile 
range) as appropriate for the data distribution. Categorical data were described as counts and proportions (n/N 
[%]). The sudent's t-test, Wilcoxon rank sum test and the Wicoxon sign rank test were used to compare 
continuous and interval groups. Fisher's exact or Chi-squared tests were used to compare categorical groups. 
Repeated measures ANOVA was planned for testing within and between group differences in eGFR at different 
time points, grouped by presence or absence of UTI. However, due to differences in timing of measurements, this 
analysis could not be performed. The differences in eGFR pre-/ post- PCN, were stratified according to presence 
or absence of UTI. Z-test for differences in proportions were used to compare proportions of patients with 
improved / deteriorated CKD stage following PCN between groups with / without UTI. We performed an 
exploratory multiple linear regression to evaluate the impact of UTI or worst eGFR outcome. The regression 
analysis was not planned before the data was analysed. The a priori level of significance was set at 0.05. Statistical 
analysis was performed using RStudio Team (2016). RStudio: Integrated Development for R. RStudio, Inc., Boston, 
MA URL http://www.rstudio.com/. 
e. Results 
We identified 90 patients that fulfilled our inclusion criteria. The most common cancers in men were bladder 59% 
(n=32), prostate 20% (n=ll), lymphoma 7% (n=4), and colorectal 4% (n=2). The most common cancers in women were 
cervix 64% (n=23), bladder 19% (n=7), lymphoma 6% (n=2), colorectal 6% (n=2) and endometrial 6% (n=2). Men were 
of higher median (IQR) age, 60 (56, 67) years, compared to women, 48 (40, 67) years. 64% (58/90) of patients had 
bilateral PCN procedure (as opposed to a unilateral procedure). 52% (47 /90) of patients developed at least one post-
PCN UTI during the 6-month observation period. Table 1 reports on the demographic data. 
Age is bi modally distributed, largely due to differences in distribution between males and females. (Figure 2). 
Grouping of age by presence or absence of UTI demonstrates the weight of post-PCN UTls which occurred in older 
patients (Figure 3). There is no apparent interaction between sex and UTI status for distribution of age variable (See 
supplemental Figure 4). 
The eGFR variable is skewed at each interval (pre-PCN, best post-PCN and worst post-PCN. The distributions for eGFR 
are similar between males and females at each interval. 
Timing of measurements 
Median (IQR) timepoint of pre-PCN eGFR measurement was 1.0 (2.0, O) day pre-PCN, for best post-PCN eGFR 
measurement was 13.0 (6.0, 26.0) days post-PCN, and for worst post-PCN measurement it was 33.5 (14.0, 92.5) days 
post-PCN (Figure 6). The worst eGFR measurement occurred a median 33 (20, 49) days after the best eGFR 
measurement (p-value < 0.001, pseudomedian difference by Wilcoxon sign rank test). In 69% (62/90, [95% Cl: 58%, 
78%]) of patients the best eGFR measurement occurred before the worst eGFR measurement. In 8% (7 /90, [3%, 16%1) 
of patients the best eGFR measurement occurred after the worst eGFR measurement. These proportions were 
significantly different from one another (Chi-squared test for equality of proportions, p-value < 0.001). 
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eGFR response 
Pre-PCN eGFR, median (IQR), was 9 (5, 26). Post-PCN eGFR improved to 48 (30, 75) before deteriorating to 23 (9, 44) 
within the six-month follow-up window (Figures 7 and Table 3). The (pseudo)median (95% Cl) difference between pre-
PCN eGFR and best eGFR post-PCN was 30 (25, 26). The (pseudo)median (95% Cl) difference between pre-PCN eGFR 
and worst post-PCN eGFR after was 8.5 (4, 13.5). The (pseudo)median {95% Cl) difference between eGFR from best to 
worst post PCN value was -25 (-20.5, -29.5). See also Table 3 for pairwise comparison and false detection rate adjusted 
p-values. 
CKD stage response 
Pearson's Chi-squared test supports independence between CKD stage and interval of measurement; p-value < 0.001. 
Worst CKD staging post-PCN was consistently better than CKD staging before PCN (p-value 0.0008, simple ordinal 
regression with cumulative links model). These differences are maximised by the study design that sought to report 
best and worst values after baseline measurement (Figure 8 and Table 6). 
Analysis of interaction between eGFR response and development of post-PCN UT/ 
Using simple linear regression to estimate the effect of UTI status on worst eGFR after PCN, the crude estimate of 
effect {95% Cl) is -5.10 (-11.54, 1.36) eGFR units, p-value = 0.120, R-squared = 0.03. 
Table 5 reports a multiple linear regression for predicting worst eGFR post-PCN. Adding the recorded predictor {eGFR 
baseline, eGFR improvement post-PCN, Age, Sex, Laterality, and cancer type) into the model improves performance, 
Adjusted R-squared = 0.37, F-statistic = 6.266 on 10 and 79 degrees of freedom, p-value < 0.0001. In this model the 
adjusted estimate of UTI effect {95% Cl) is -6.15 (-11.43, -0.87). Despite some improvement in performance through 
log transformation of the baseline eGFR variable, this model demonstrates significant heteroskedasticity in residual 
diagnostics. The source of non-constant variance is likely due to the non-continuous nature of the eGFR variable 
above values of 60. (Refer to supplemental Figures 9a-c and lOa-d for regression diagnostics.) 
Analysis of interaction between change in CKD stage post-PCN and development of post-PCN UT/ 
Proportions appear similar when comparing those with and without post-PCN UTls in the alluvial piots (Figure 11). The 
proportional breakdown of the worst CKD stage appears slightly better (fewer cases with CKD stage 4 and 5) in those 
without UTI compared to those who developed at least one UTI post-PCN. There are also markedly fewer 
deteriorations in CKD stages between best and worst post-PCN interval in those without UTI (42%, 18/43) compared 
to those with at least one postoperative UTI {72%, 34/47). The difference (95% Cl) in proportions is 30% (9%, 52%), p-
value = 0.0067 (2-sample test for equality of proportions). 
Other demographics 
Looking at age distribution and renal function response, the younger age-group (<SOyears) showed a good response in 
renal function up to six months post-PCN in 46% (13/28) of patients. In the age-group 50 - 65 years, a good response 
was found in 41% (14/34) of patients and in the group 2'.65 years a good response was found in 32% (9/28) of patients. 
UTI incidence according to age-groups: The group 2'.65 years had incidence of 61% (17 /28 patients), the group 50 - 65 
years, 59% (20/34 patients) and the group <SO years, 36% (10/28 patients). 
In the patients who had bilateral PCN (58 patients), 45% (26/58 patients) had improved CKD-stage up to six months 
post-PCN, while in the group of patients who had unilateral PCN (32 patients), only 22% (7/32 patients) had improved 
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CKD stage up to six months post-PCN. The incidence of UTI in the bilateral PCN patients was 55% (32/58 patients), 
while the unilateral PCN patients had an incidence of 47% (15/32 patients). 
Comparing different cancers and percentage of good responders in renal function post-PCN [total]: Bladder Ca 49% 
(19/391, Cervical Ca 30% (7 /23], Haematological malignancies (7 Lymphoma and 1 Multiple myeloma patients) 86% 
[6/7] and Prostate Ca 18% [2/11]. 
f. Discussion 
Summary of main findings 
On average, patients in our study experienced and initial early improvement in renal function (around two weeks 
post-PCN) followed by a deterioration towards baseline (around one month after PCN). 52% (n=47) of our patients 
developed at least one UTI following PCN. UTI events were associated with worse eGFR outcome by multiple linear 
regression, and worse CKD staging by stratified analysis 
Limitations of our study 
Use of a retrospective design limited our ability to analyse the interaction between UTI and response in renal function. 
The reason for this is because the outcome of interest was not recorded at standard intervals, and there was large 
variance in the time at which best and worst renal function values were recorded. Prospective studies can overcome 
this problem by standardising timepoints for outcome assessment. 
We acknowledge that using the CKD staging has not been validates in this specific setting. Our primary research 
question was adequately answered using the CKD stages. 
Another limitation is the fact that the laboratory service we used do not give specific values of eGFR for values 
>60ml/min. We therefor decided to use CKD stage 2 and eGFR of 75ml/min for all eGFR >60ml/min. The non-
continuous nature of eGFR variable introduced difficulty with analysis. This can be overcome by calculating eGFR 
throughout the range, or using serum creatinine concentration instead of eGFR in regression analysis. We might have 
obtained more accurate data if we could have distinguish between CKD stages 1 and 2. 
Interpretation 
eGFR trends post-PCN 
To determine eGFR trends from pre-PCN to best and worst eGFR we evaluated the timing when the different values 
were obtained (Figure 6). The majority of patients (69%) had a best eGFR measurement prior to worst eGFR 
measurement. Only 8% of patients had their best eGFR measurement after their worst eGFR measurement. 
These findings support the hypothesis that patients experience an initial improvement in renal function, followed by a 
deterioration in function towards pre-PCN values. Available literature is unclear on this topic. This is an important 
factor to acknowledge when counselling patients for PCN in this setting. Nariculam et al. (10] found that among 
prostate cancer patients who underwent either unilateral or bilateral PCN, no major differences in post-PCN 
creatinine levels were seen. They showed little difference in the serum creatinine levels at the time of death, 
suggesting that survival after PCN insertion is based on the aggressiveness of the prostate cancer as opposed to the 
number of nephrostomies inserted. This may explain our patients' worsening renal function after initial improvement. 
Another reason for this deterioration in renal function can be the development of UTI, which had shown to be a risk 
factor for AKI [7]. Our cohort had a higher incidence of UTI post PCN when compared to available literature, indicating 
higher risk for developing AKI. 
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eGFR and CKD stage response post-PCN 
We investigated eGFR/CKD stage at three intervals (baseline, best and worst values post-PCN). (Figures 7&8 and Table 
3). CKD stage improved significantly following PCN with change from pre-PCN to best post-PCN CKD stage, and 
deteriorated again from pre-PCN to worst post-PCN CKD stage. Possible causes for this deterioration include 
progression of primary malignancy, dislodgement/blockage of nephrostomy tubes, pre-renal causes (excluding UTI) 
and acquiring urinary tract infection secondary to foreign body (nephrostomy tube) in situ. 
Unlike similar studies on this topic, this study design sought to report best and worst values after baseline 
measurement (Figure 8). Our results call in to question the role of PCN in advanced malignancy as we have shown that 
initial improvements in eGFR and CKD stage are short-lived. There are few other studies which have investigated or 
shown this conclusively. 
Interaction between renal function and development of UT/ post-PCN 
The incidence of UTI in our study (52%) was higher than the reported literature, with reported incidences of UTl/sepsis 
post-PCN between 15% [8] and 22.7% (4]. 
Our secondary objective was to analyse the interaction between eGFR response and the development of post-PCN 
UTI. Multiple linear regression (figure 9) showed that patients who develop one or more post-PCN UTls have a 6.15 
unit lower eGFR at their worst eGFR measurement than those who do not. This could be a useful prognostic indicator 
in the clinical setting. The prognostication models available do not include this as a factor affecting survival. 
Prospective research investigating UTls and its effect on renal function and subsequent survival in the malignant PCN 
setting might provide better clarity on the subject. 
This multiple linear regression is not a perfect model. Non-constant variance remains a problem despite 
transformation of the pre-PCN eGFR variable. This is most likely due to the mixed nature of the eGFR variables. In this 
dataset eGFR is recorded as a continuous variable up to 60, but then it becomes categorical, with all values greater 
than 60 being recorded as 75. Future studies should find a way to calculate absolute eGFR values through the full 
range of the variable. The model further assumes that all important predictors of worst eGFR outcome were available 
in this dataset. The model does not consider any temporal information regarding when a given patient experienced 
the worst post-PCN eGFR. 
Proportional breakdown of the worst CKD stage is better in the group without UTI (Figure 11). There were also 
markedly fewer deteriorations in CKD stages between best and worst post-PCN interval in the patients without UTI. 
This findings supports our hypothesis that UTI is associated with poor renal function response post-PCN. The poor 
response in patients who developed UTI post-PCN also applies to patients who initially responded well. 
It is described that UTI can cause AKI [7], but in the specific setting of our cohort, evidence is scarce. This finding 
warrants further investigation in a prospective trial environment. Once the hypothesis is confirmed prospectively, 
interventions like using prophylactic antibiotics and maybe closed system drainage systems (as opposed to open 
ended nephrostomies with a drainage bag connected to the skin) should be explored in future research. Regular 
screening for bacteriuria and treating this can also be explored. It is important to note that most knowledge and 
management strategies regarding asymptomatic bacteriuria relates to the bladder/ voided samples and not in this 
specific setting of a possible immunocompromised patient having a PCN tube/sin situ. This might add an additional 
scenario where asymptomatic bacteriuria should be treated aggressively. 
Other considerations 
Investigating age distribution, it appears that older patients had worse renal function response and more UTls. We 
know that older patients and patients with PCN are more at risk to develop UT!. They usually are more prone to 
developing AKI post UTI [7]. This will need to be proven with statistical analysis. 
A total of 64% of our patients had bilateral PCN. This is in line with the reported literature of incidences ranging from 
22% [1] and 72% (10]. The patients who had bilateral PCN showed a higher percentage of improved CKD-stage up to 
six months post-PCN, when compared to the patients who only had unilateral PCN. Interestingly, the incidence of UTI 
in the bilateral PCN patients was higher compared to the patients with unilateral PCN 55% vs 47%). This is contrary to 
our hypothesis that a higher incidence of UTI is associated with poorer renal function response. Nariculam et al. (10] 
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concluded in their trial of prostate cancer patients that bilateral or unilateral PCN did not influence renal function, 
measured at the time of death. 
When we compare different cancers and the percentage of good responders in renal function post-PCN, it appeared 
that prostate cancer did the worst in terms of renal function response post-PCN. This is however not statistically 
significant in our series. One reason for this finding can be due to the older population group that usually gets 
diagnosed with prostate cancer, who are prone to UTI and AKI. Prostate cancer is often associated with bladder outlet 
obstruction, sometimes requiring catheterisation and/or surgery, all of which increase the risk for UTI and renal 
failure. The biological aggressiveness of advanced prostate cancer can also contribute to the poor renal function 
response. This was demonstrated by Nariculam et al. [10] who reported that renal function is dependent on the 
aggressiveness of the primary tumour (prostate cancer in their study) and not on the amount of PCN tubes (bilateral 
or unilateral). 
Conclusion 
Our study confirmed a similar renal function trend post-PCN for malignant ureteric obstruction across different 
demographics. Although most patients' renal function initially improves post-PCN, the general trend for the majority 
of patients is to deteriorate towards pre-PCN eGFR and CKD stage values. 
Urinary tract infections appear to play and important role in poor renal function response within six months post-PCN. 
This however was difficult to prove statistically and should be evaluated prospectively in future studies. 
Other demographic factors that appear to have an influence on renal function response post-PCN include type of 
malignancy, age and laterality of PCN, and theses might require further investigation in future. 
In our study, the only modifiable risk factor associated with poor response in renal function post-PCN, seems to be 
UTls. This is perhaps an area to explore, to prevent UTls and in doing so increase the probability of better renal 
function response post-PCN for malignant ureteric obstruction. 
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h. Tables 
Table 1: Patient characteristics (N=90), group by presence or absence of one or more post-PCN UTls. 
Variable No UTI ~1 UTI Total 
Age 
Mean 55 58 56 
Sd 15 12 14 
Min 24 31 24 
p25 42 56 46 
Median 56 60 59 
p75 66 67 67 
Max 88 78 88 
Mode 40 56 56 
Sex 
Female 19 17 36 
Male 24 30 54 
Cancer type 
Bladder 16 23 39 
Cervix 14 9 23 
Prostate 4 7 11 
Colo rectal 2 2 4 
Lymphoma 3 3 6 
Endometrial 1 1 2 
Other 3 2 5 
Laterality of procedure 
Unilateral 17 15 32 
Bilateral 26 32 58 
25 
Table 2. Patient outcomes grouped by presence or absence of post-PCN UTI 
Variable No UTI (N=43) >=1 UTI (N=47) p-value Total (N=90) 
Timing of measurement 
Preoperative 
mean (sd) -2.1 (3.1) -1.2 (1.5) -1.6 (2.4) 
median (p25, p75) -1. (-2.5, 0.) -1.0 (-1.5, 0.) 0.414t -1.0 (-2.0, 0.) 
range -13, 0 -6, 0 -13, 0 
Best postoperative 
mean (sd) 17.5 (24.6) 28.9 (33.5) 23.4 (29.9) 
median (p25, p75) 11. (4.5, 17.5) 16. (9.5, 31.5) 0.018t 13. (6., 26.) 
range 1,148 1,154 1,154 
Worst postoperative 
mean (sd) 37.7 (45.4) 68.6 (52.4) 53.8 (51.3) 
median (p25, p75) 18. (11., 40.) 45. (24.5, 112.) 0.0004t 33.5 (14., 92.5) 
range 2,174 4,181 2,181 
GFR 
Preoperative 
mean (sd) 19 (20) 19 (22) 19 (21) 
median (p25, p75) 11 (6, 29) 7 (4, 24) 0.342t 9 (5, 26) 
range 2, 75 2, 75 2, 75 
Best postoperative 
mean (sd) 45 {24) 51 (21) 48 (22) 
median (p25, p75) 41 (26, 75) 52 (36, 75) 0.158t 48 (30, 75) 
range 7, 75 9, 75 7, 75 
Worst postoperative 
mean (sd) 32 (23) 25 (20) 28 (22) 
median (p25, p75) 29 (14, 48) 19 (8, 38) 0.128t 23 (9, 44) 
range 2, 75 3, 75 2, 75 
CKD stage 
Preoperative 
<=2 3 (7%) 4 (9%) 7 (8%) 
3 8 {19%) 7 (15%) 15 (17%) 
4 5 (12%) 6 (13%) 0.213+ 11 (12%) 
5 27 {63%) 30 {64%) 57 (63%) 
Best postoperative 
<=2 13 (30%) 15 (32%) 28 {31%) 
3 17(40%) 23 (49%) 
0.213+ 
40 {44%) 
4 8 (19%) 6 {13%) 14 (16%) 
5 5 {12%) 3 {6%) 8 (9%) 
Worst postoperative 
<=2 12 (28%) 20 {43%) 9 {10%) 
3 10 {23%) 12 (26%) 27 (30%) 
4 15 (35%) 12 (26%) 0.238+ 22 (24%) 
5 6 (14%) 3 (6%) 32 (36%) 
tWilcoxon Rank Sum test, +Chi-squared test with continuity correction 
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Table 3. Pairwise comparison using Wilcoxon sign rank test with p-value adjustment by false detection rate 
(FDR) method: 
Preoperative eGFR Best postoperative eGFR 
Pseudo- 95%CI p-value Pseudo- I 95%CI I p-value 
median median 
Best postoperative eGFR 30 25,36 1.0e-14 -
Worst postoperative eGFR 8.5 4, 13.5 9.4e-05 -25 I 20.5, 29.5 I 7.9e-13 
Table 4. CKD stage by interval 
CKD stage Pre-PCN Best Post-PCN Worst Post-PCN 
2+ 7 28 9 
3 15 40 27 
4 11 14 22 
5 57 8 32 
Table 5. Multiple linear regression for predicting worst eGFR post PCN. 
Estimate P-value Lower 95% Cl Upper 95% Cl 
(Intercept) -3.66 0.797 -31.38 24.07 
>=1 UTI -6.15 0.025 -11.43 -0.87 
Ln(Pre-PCN eGFR) 11.24 2.51e-06 6.90 15.57 
eGFR response(Pre~Best) 0.57 7.46e-07 0.36 0.77 
Age -0.16 0.370 -0.51 0.19 
Sex (male) 0.15 0.972 -8.07 8.37 
Laterality (bilateral) -1.99 0.540 -8.32 4.35 
Reference diagnosis (bladder ca.) 
Diagnosis (cervix ca.) 8.00 0.117 -1.89 17.88 
Diagnosis (prostate ca.) 2.71 0.598 -7.31 12.72 
Diagnosis (lymphoma) -5.78 0.381 -18.64 7.08 
Diagnosis (other) -0.06 0.994 -14.43 14.31 
Adjusted R-squared = 0.37, F-statistic = 6.266 on 10 and 79 degrees of freedom, p-value = 5.402e-07 
Table 6. Cumulative probabilities of CKD categories at three time intervals. 
CKD Baseline Best Worst 
n proportion n proportion n proportion 
5 57 0.63 8 0.09 32 0.36 
4-5 68 0.76 22 0.24 54 0.60 
3-5 83 0.92 62 0.69 81 0.90 
1-5 90 1.00 90 1.00 90 1.00 
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i. Illustrations (Figures) 
Figure 2. Density plot of age variable grouped by sex 
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Figure 3. Density plot of age variable grouped by presence or absence of post-PCN UTI 
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Figure 6. Boxplots of timing of eGFR measurement 
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Figure 7. Boxplots of eGFR at three intervals grouped by presence or absence of post-PCN UTI 
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Figure 8. Histograms of CKD stages at three time intervals (pre-PCN, best post-PCN, and worst post-
PCN). 
5 4 3 2 
Pre-PCN Best Post-PCN Worst Post-PCN 
~ l 
I I I I I I I I I I I I 
5 4 2 5 4 2 
CKD stage 
Figure 11. Alluvial plots of patient CKD stage at three intervals. Comparing those at least one 
postoperative UTI event to those without any postoperative UTI events. Worst stage is dark grey at 
top of bars, best stage is light grey at bottom of bars. 
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j. Units of Measurement 
Renal function: Measured by estimated Glomerular Filtration Rate (eGFR) in ml/min per 1.73 m2 according to 
the MDRD formula. 
UTI: Measured in CFU/ml (colony-forming units per millilitre) 
Serum creatinine: Measured in umol/L 
k. Abbreviations and Symbols 
AKI: Acute kidney injury 
CFU/mL: colony-forming units per millilitre 
CKD: chronic kidney disease 
eGFR: estimated Glomerular Filtration Rate 
MC&S: Microscopy, Culture & Sensitivity 
MDRD: Modification of Diet in Renal Disease (MDRD) equation 
PCN: percutaneous nephrostomy 
UTI: urinary tract infection 
UTls: urinary tract infections 
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Figure 4. Interaction plot of age variable grouped by sex and presence or absence of post-PCN UTI 
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Figures Sa-c. Density distributions of eGFR at three intervals, grouped by sex. 
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Figures 9a-c. Diagnostic plots for multiple linear regression 
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Figures 10a-d. Added variable plots of UTI and continuous predictors in multiple linear regression. 
Added-Variable Plots 
0 0 0 0 
.... 0 
0 0 0 O 0 0 
0 0 0 
..,. 0 
0 0 ~ 0 0 ~ 0 0 .. 0 .. 
,:; N 0 J' 0 0 ,:; 0 Oo 0 0 0 0 D 0 
0 00 N 
f! oo ~ 
0 0 
0 Oo 0 0 
", 
0 0 0 0 
" 0 0 0 Cl'. 0 0 0 0 Cl'. LL 0 0 0 o(/>o 0 LL <g (!) 00 0 0 0 
" 0 
0 0 D ~ 0 'o 0 
0 0 0 0 ~ 0 0 0 0 
'o 00 0 
-1 .0 -0.5 0.0 0.5 1.0 -1 0 2 
UTI_bin.L I others GFR _pre _log I others 
0 D 0 0 0 
..,. 
0 0 
0 0 0 0 
0 0 0 0 
0 
..,. 
0 0 0 0 ~ 0 ~ D 0 
., .. N 
,:; 0 ,:; 
0 0 8 0 0 0 0 0 0 D 0 0 0 0 
N 0 0 0 0 
o
0 
oi I!! 0 0 ~ • 0 0 8 0 0 0 
"1 0 " 
D 
0 0 
0 0 
0 
oc D 0 Cl'. 0 0 0 ~ 0 0 .o 8g 0 ~ 0 LL 0 LL 00 
<g 0 0 0 (!) 0 0 00 ., 
0 0 
"' 
D 
0 $0 rP D 0 ~ ~ 0 0 g 0 
0 
,,,°o 
0 0 0 
0 0 00 
-40 -20 0 20 40 -30 -20 -10 0 10 20 
GFR_difference I others Age I others 
35 
Appendix ii 
19 February 2019 
HREC Rl!F: 097 /2019 
Dr L Kaestner 
Urology 
E26, 0MB 
Dear Or Kaestner 
UNIVERSITY OF CAPE TOWN 
Faculty of Health Sciences 
Hum■n ReH■rch Ethlca Committee 
Room E53-46 Old Main Bulldlnc, 
Groote Sdluur H0tpltal 
Omervatory 7925 
Telephone [021] 406 6626 
em•II: shurettn,thQmaseuctac,za 
Webstt.: www, bea!th .uct,ac,za/fhs/a:search/humanetblcs/l'Qm:Js 
PROJ!CT TITLE: DO PERCUTANEOUS NEPHROSTOMIES FOR MAUGNANT OBSTRUtnVE 
UROPATHY IMPROYI! R2NAL FUNCTION SIX MONTHS INTERVfNTION? {MMED CANDIDA!!: 
DR C.E DE WET) 
Thank you for submitting your study to the Faculty of Health Sciences Humlin Research Ethics 
Committee. 
It Is a pleasure to Inform you that the HREC has formally approved the above-mentioned study. 
Approval I• granted for one year until the 28 February 2020. 
Please submit a progress form, uslng the standardised Annual Report Form If the study continues 
beyond the approval period. Please submit a Standard Closure form if the study Is completed within the 
approval period, 
(Forms can be found on our website: www,heafth.uctRac,zaMhs/research/humanethic&lfocm�i) 
Pl•••• quote the HREC REF in all your correapondence. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
Investigator. 
Please note that for all studies approved by the HREC, the principal Investigator Dlllll obtain 
appropriate instltutlonal approval, where necessary, before the research may occur. 
You,s •lncerely 
PROFESSOR H &LOCKMAN 
CHAIR'6$QN. FHS HUMAN RESEARCH ETHICS COMMITTEE 
Federal Wide Assurence Number: FWA00001637. 
Instttutlonal Review Board (IRB) number: IRB00001938 
This serves to confirm that the University of cape Town Human Research Ethics Committee complies 
to the Ethics Standards for Clinical Research with a new drug In �tients, based on the Medics! 
HREC 097 /2019 
signature removed to avoid exposure online
Research Council (MRC-SA), Food and Drug Administration (FDA-USA), Intematlonal Convention on 
Harmonisation Good Cllnlcal Practice (ICH GCP), South African Good Cllnlcal Practice Guldellnes (DoH 
2006), based on the Association of the British Pharmaceutical Industry Guldellnes (ABPI), and 
Oeclaratlon of Helsinki (2013) guldellnes. 
The Human Research Ethics Committee granting this approval Is In compliance with the ICH 
Hannonlsed Tripartite Guldellnes E6: Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) 
and FDA Code Federal Regulation Part so, 56 and 312. 
HREC 097/2019 
Appendix iii 
UNIVERSiTY OF CAPE TOWN 
Dr C De Wet 
Department of Surgery 
University of Cape Town 
Dear Dr De Wet 
RE: Project 2018/094 
Department of Surgery 
Departmental Research Committee 
Dr Timothy Pennel 
D24 Office, Groote Schuur Hospital 
Observatory 7925 
South Africa 
Tel (021) 404 3430 
Email: tim.pennel@uct.ac.za 
28 Jan 2019
PROJECT TITLE: Do Percutaneous Nephrostomies For Malignant Obstructive Uropathy Improve 
Renal Function Six Months Post Intervention? 
The above protocol has been reviewed by the Department of Surgery Research Committee. I am 
pleased to inform you that the committee approved the scientific merit of the study, and endorse 
the protocol for submission to the relevant ethics committee. 
Although this letter serves as confirmation that the above protocol has successfully passed 
through the surgical DRC, respective ethics committees still require DRC chair signature before 
submission. 
Please use the above project number in all future correspondence, 
Yours sincerely 
DR TIMOTHY PENNEL 
CHAIRMAN: RESEARCH COMMITTEE 
"OUR MISSION is to be an outstanding teaching and research university, educating for life and addressing the challenges facing our society." 
signature removed to avoid exposure online
Appendix iv 
Unauthorized reproduction of this article is prohibited. 
Recommendations for the Conduct, Reporting, Editing, and 
Publication of Scholarly Work in Medical Journals 
Updated December 2018 
I. About the Recommendation& 
A. Purpose of the Recommendations 
B. Who Should Use the Recommendations? 
C. History of the Recommendations 
IL Roles and Responsibilities of Authors, Contributors, 
Reviewers, Editors, Publishers, and Owners 
A. Defining the Role of Authors and Contributors 
1. Why Authorship Matters 
2. Who Is an Author? 
3. Non-Author Contributors 
B. Conflicts of Interest 
I. Participant~ 
a. Aurhors 
h. Peer Revinvers 
c. Editors and Journal Staff 
2. Reporting Conflicts of Interest 
C Responsibilities in the Submission and Peer-Review 
Process 
1. Authors 
a. Predatory or Pseudo-Journals 
2. Journals 
a. Confidentiality 
b. Timeliness 
c. Peer Review 
d. Inregrity 
e. Journal Metrics 
3. Peer Reviewers 
D. Journal Owners and Editorial Freedom 
1. Journal Owners 
2. Editorial Freedom 
E. Protection of Research Participants 
III. Publishing and Editorial lssues Related to Publicatio11 
in Medical Journals 
A. Corrections, Retractions, Republications. and Ver-
sion Control 
B. Scientific Misconduct, Expressions of Concern, 
and Retraction 
C. Copyright 
D. Overlapping Publications 
l. Duplicate Submission 
2. Duplicate and Prior Publication 
3. Acceptable Secondary Publication 
4. Manuscripts Based on the Same Database 
E. Correspondence 
F. Fees 
G. Supplements, Theme Issues, and Special Series 
H. Sponsorship of Partnerships 
I. Electronic Publishing 
J. Advertising 
K. Journals and the Media 
L. Clinic.ii Trial, 
1. Registration 
ii. Data Sharing 
IV. Manuscript Preparation and Submission 
A. Preparing a Manuscript. for Submission to a Med-
ical Journal 
I. General Principle;, 
2. Reporting Guidelines 
3. Manuscript Sections 
a. Tide Page 
b. Ab~tract 
c. Introduction 
d. Methods 
i. Selection and Description of Participants 
ii. Technical Information 
iii. Statistics 
e. Results 
f. Discussion 
g. References 
i. Ceneral Considerations 
ii. Style and format 
h. Tables 
i. Illustrations (Figures) 
J· Units of Measurement 
k. Abbreviations and Symbols 
B. Sending the Manuscript to the Journal 
I. ABOUT THE RECOMMENDATIONS 
A. Purpose of the Recommendations 
ICMJE developed these recommendations to review 
best practice and ethical standards in the conduct and re-
porting of research anJ other material published in medical 
journals, and to help authors, editors. and others involved 
in peer review and biomedical publishing create and dis-
tribute accurate, clear, reproducible, unbiased medical journal 
articles. The recommendations may al~o provide useful in-
sights into the medical editing and publishing process for the 
media. patients and their families, and general readers. 
B. Who Should Use the Recommendations? 
These recommendations are intended primarily for use 
by authors who might submit their work for publication to 
ICMJE member journals. Many non-ICMJE journals vol-
untarily use these recommendations (see \vww.icmje.org 
/journals-following-the-icjme-recommendations/). The ICMJE 
encourages that use but has no authority to monitor or 
enforce it. In all cases, authors should use these recommen-
dations along with individual journals' instructions ro au-
thors. Authors should also consult guidelines for the re-
porting of specific study types (e.g., rhc CONSORT 
11 
[rich<i~im/z:;;=-aim/zai44418/zai0001d18a I murkarv I 5=96 j 11/29/18 I 8:52 J Art: n 
Unauthorized reproduction of this article is prohibited. Recommendarions for rhe Conducr, Reporting, Edi ring, and Publication of Scholarly Work in Medical Journals guidelines for the reporting of randomized trials); see www.equator-network.org. Journals that follow these recommendations are en­couraged to incorporate them into their instructions to authors and to make explicit in those instructions that they follow ICMJE recommendations. Journals that wish to be identified on the ICMJE website as following these recom­mendations should notify the ICMJE secretariat at www .icmje.org/journals-following-the-icmje-recommendations /journal-listing-request-form/. Journals that in the past have requested such identification but who no longer fol­low ICMJE recommendations should use the same means to request removal from this list. The ICMJE encourages wide dissemination of these recommendations and reproduction of this document in its entirety for educational, not-for-profit purposes without regard for copyright, but all uses of the recommendations and document should direct readers to www.icmje.org for the official, most recent version, as the ICMJE updates the recommendations periodically when new issues arise. 
C. History of the RecommendationsThe ICMJE has produced multiple editions of thisdocument, previously known as the Uniform Require­ments for Manuscripts Submitted to Biomedical Journals (URMs). The URM was first published in 1978 as a way of standardizing manuscript format and preparation across journals. Over the years, issues in publishing that went well beyond manuscript preparation arose, resulting in the de­velopment of separate statements, up-dates ro the docu­ment, and its renaming as "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals" to reflect its broader scope. Previous versions of the document may be found in the "Archives" section of www.icmje.org. 
II. ROLES AND RESPONSIBILITIES OF AUTHORS,
CONTRIBUTORS, REVIEWERS, EDITORS, PUBLISHERS,
AND OWNERS
A. Defining the Role of Authors and Contributors
1. Why Authorship MattersAuthorship confers credit and has important aca­demic, social, and financial implications. Authorship also implies responsibility and accountability for published work. The following recommendations are intended to ensure that contributors who have made substantive intel­lectual contributions to a paper are given credit as authors, but also that contributors credited as authors understand their role in taking responsibility and being accountable for what is published. Because authorship does not communicate what con­tributions qualified an individual to be an author, some journals now request and publish information about the contributions of each person named as having participated in a submitted study, at least for original research. Editors are strongly encouraged to develop and implement a con- tributorship policy. Such policies remove much of the am­biguity surrounding contributions, but leave unresolved the question of the quantity and quality of contribution that qualify an individual for authorship. The ICMJE has thus developed criteria for authorship that can be used by all journals, including those that distinguish authors from other contributors. 2. Who Is an Author?The ICMJE recommends that authorship be based onthe following 4 criteria: 1. Substantial contributions to the conception or de­sign of the work; or the acquisition, analysis, or interpre­tation of data for the work; AND 2. Drafting the work or revising it critically for im­portant intellectual content; AND 3. Final approval of the version to be published; AND4. Agreement to be accountable for all aspects of thework in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investi­gated and resolved. In addition to being accountable for the parts of the work he or she has done, an author should be able to identify which co-authors are responsible for specific other parts of the work. In addition, authors should have confidence in the integrity of the contributions of their co-authors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged-see Section II.A.3 below. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not in­tended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by de­nying them the opportunity to meet criterion #s 2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript. The individuals who conduct the work are responsible for identifying who meets these criteria and ideally should do so when planning the work, making modifications as appropriate as the work progresses. We encourage collabo­ration and co-authorship with colleagues in the locations where the research is conducted. It is the collective respon­sibility of the authors, not the journal to which the work is submitted, to determine that all people named as authors meet all four criteria; it is not the role of journal editors to determine who qualifies or does not qualify for authorship or to arbitrate authorship conflicts. If agreement cannot be reached about who qualifies for authorship, the institu­tion(s) where the work was performed, not the journal editor, should be asked to investigate. If authors request removal or addition of an author after manuscript submis­sion or publication, journal editors should seek an expla­nation and signed statement of agreement for the requested 
www.icmje.org 
! rich4/zai-aim/zai-aim/zai44418/zai0001d18a ! murkarv ! S=96 ! 11/29/18 I 8:52 [ Art: I [ 
Unauthorized reproduction of this article is prohibited. 
Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals 
change from all listed authors and from the author to be 
removed or added. 
The corresponding author is the one individual who 
takes primary responsibility for communication with the 
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the corresponding author should specify the group name if 
one exists, and clearly identify the group members who can 
take credit and responsibility for the work as authors. The 
byline of the article identifies who is directly responsible 
for the manuscript, and MEDLINE lists as authors which-
ever names appear on the byline. If the byline includes a 
group name, MEDLINE will list the names of individual 
group members who are authors or who are collaborators, 
sometimes called non-author contributors, if there is a note 
associated with the byline clearly stating that the individual 
names are elsewhere in the paper and whether those names 
are authors or collaborators. 
3. Non-Author Contributors 
Contributors who meet fewer than all 4 of the above 
criteria for authorship should not be listed as authors, but 
they should be acknowledged. Examples of activities that 
alone (without other contributions) do not qualify a con-
tributor for authorship are acquisition of funding; general 
supervision of a research group or general administrative 
support; and writing assistance, technical editing, language 
www.icmje.org 
editing, and proofreading. Those whose contributions do 
not justify authorship may be acknowledged individually 
or together as a group under a single heading (e.g., "Clin-
ical Investigators" or "Participating Investigators"), and 
their contributions should be specified (e.g., "served as scien-
tific advisors," "critically reviewed the study proposal," "col-
lected data," "provided and cared for study patients", "partic-
ipated in writing or technical editing of the manuscript"). 
Because acknowledgment may imply endorsement by 
acknowledged individuals of a study's data and conclu-
sions, editors are advised to require that the corresponding 
author obtain written permission to be acknowledged from 
all acknowledged individuals. 
B. Conflicts of Interest 
Public trust in the scientific process and the credibility 
of published articles depend in part on how transparently 
conflicts of interest are handled during the planning, im-
plementation, writing, peer review, editing, and publica-
tion of scientific work. 
A conflict of interest exists when professional judg-
ment concerning a primary interest (such as patients' wel-
fare or the validity of research) may be influenced by a 
secondary interest (such as financial gain) . Perceptions of 
conflict of interest are as important as actual conflicts of 
interest. 
Financial relationships (such as employment, consul-
tancies, stock ownership or options, honoraria, patents, 
and paid expert testimony) are the most easily identifiable 
conflicts of interest and the most likely to undermine the 
credibility of the journal, the authors, and science itself. 
However, conflicts can occur for other reasons, such as 
personal relationships or rivalries, academic competition, 
and intellectual beliefs. Authors should avoid entering in to 
agreements with study sponsors, both for-profit and non-
profit, that interfere with authors' access to all of the 
study's data or that interfere with their ability to analyze 
and interpret the data and to prepare and publish manu-
scripts independently when and where they choose. 
Authors may be required to provide the journal with the 
agreements in confidence. 
Purposeful failure to disclose conflicts of interest is a 
form of misconduct, as is discussed in Section III.B. 
1. Participants 
All participants in the peer-review and publication 
process-not only authors but also peer reviewers, editors, 
and editorial board members of journals-must consider 
their conflicts of interest when fulfilling their roles in the 
process of article review and publication and must disclose 
all relationships that could be viewed as potential conflicts 
of interest. 
a. Authors 
When authors submit a manuscript of any type or 
format they are responsible for disclosing all financial and 
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personal relationships that might bias or be seen to bias 
their work. The ICMJE has developed a Form for Disclo-
sure of Conflicts of Interest to facilitate and standardize 
authors' disclosures. ICMJE member journals require that 
authors use this form, and ICMJE encourages other jour-
nals to adopt it. 
b. Peer Reviewers 
Reviewers should be asked at the time they are asked 
to critique a manuscript if they have conflicts of interest 
that could complicate their review. Reviewers must disclose 
to editors any conflicts of interest that could bias their 
opinions of the manuscript, and should recuse themselves 
from reviewing specific manuscripts if the potential for bias 
exists. Reviewers must not use knowledge of the work 
they're reviewing before its publication to further their 
own interests. 
c. Editors and Journal Staff 
Editors who make final decisions about manuscripts 
should recuse themselves from editorial decisions if they 
have conflicts of interest or relationships that pose poten-
tial conflicts related to articles under consideration. Other 
editorial staff members who participate in editorial deci-
sions must provide editors with a current description of 
their financial interests or other conflicts (as they might 
relate to editorial judgments) and recuse themselves from 
any decisions in which a conflict of interest exists. Editorial 
staff must not use information gained through working 
with manuscripts for private gain. Editors should publish 
regular disclosure statements about potential conflicts of 
interests related to their own commitments and those of 
their journal staff. Guest editors should follow these same 
procedures. 
Journals should take extra precautions and have a 
stated policy for evaluation of manuscripts submitted by 
individuals involved in editorial decisions. Further guid-
ance is available from COPE (https://publicationethics.org 
/files/ A_Shorr_ Guide_to_Ethical_Editing. pdf) and W AME 
(http:/ /wame.org/ conflict-of-interest-in-peer-reviewed-medical 
-journals) . 
2. Reporting Conflicts of Interest 
Articles should be published with statements or sup-
porting documents, such as the ICMJE conflict of interest 
form, declaring: 
- Authors' conflicts of interest; and 
- Sources of support for the work, including sponsor 
names along with explanations of the role of those sources 
if any in study design; collection, analysis, and interpreta-
tion of data; writing of the report; the decision to submit 
the report for publication; or a statement declaring that the 
supporting source had no such involvement; and 
- Whether the authors had access to the study data, 
with an explanation of the nature and extent of access, 
including whether access is ongoing. 
To support the above statements, editors may request 
that authors of a study sponsored by a funder with a pro-
prietary or financial interest in the outcome sign a state-
ment, such as "I had full access to all of the data in this 
study and I take complete responsibility for the integrity of 
the data and the accuracy of the data analysis." 
C. Responsibilities in the Submission and Peer-Review 
Process 
1. Authors 
Authors should abide by all principles of authorship 
and declaration of conflicts of interest detailed in section 
IIA and B of this document. 
a. Predatory or Pseudo-Journals 
A growing number of entities are advertising them-
selves as "scholarly medical journals" yet do not function as 
such. These journals ("predatory"or "pseudo-journals") ac-
cept and publish almost all submissions and charge article 
processing (or publication) fees, often informing authors 
about this after a paper's acceptance for publication. They 
often claim to perform peer review but do not and may 
purposefully use names similar to well established journals. 
They may state that they are members of ICMJE but are 
not (see www.icmje.org for current members of the 
ICMJE) and that they follow the recommendations of or-
ganizations such as the ICMJE, COPE and WAME. Re-
searchers must be aware of the existence of such entities 
and avoid submitting research to them for publication. 
Authors have a responsibility to evaluate the integrity, 
history, practices and reputation of the journals to which 
they submit manuscripts. Guidance from various organiza-
tions is available to help identify the characteristics of rep-
utable peer-reviewed journals (www.wame.org/identifying-
predatory-or-pseudo-journals and www.wame.org/about/ 
principlesof-transparency-and-best-practice). Seeking the 
assistance of scientific mentors, senior colleagues and others 
with many years of scholarly publishing experience may also 
be helpful. 
2. Journals 
a. Confidentiality 
Manuscripts submitted to journals are privileged com-
munications that are authors' private, confidential prop-
erty, and authors may be harmed by premature disclosure 
of any or all of a manuscript's details. 
Editors therefore must not share information about 
manuscripts, including whether they have been received 
and are under review, their content and status in the review 
process, criticism by reviewers, and their ultimate fate, to 
anyone other than the authors and reviewers. Requests 
from third parties to use manuscripts and reviews for legal 
proceedings should be politely refused, and editors should 
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do their best not to provide such confidential material 
should it be subpoenaed. 
Editors must also make clear that reviewers should 
keep manuscripts, associated material, and the information 
they contain strictly confidential. Reviewers and editorial 
staff members must not publicly discuss the authors' work, 
and reviewers must not appropriate authors' ideas before 
the manuscript is published. Reviewers must not retain the 
manuscript for their personal use and should destroy paper 
copies of manuscripts and delete electronic copies after 
submitting their reviews. 
When a manuscript is rejected, it is best practice for 
journals to delete copies of it from their editorial systems 
unless retention is required by local regulations. Journals 
that retain copies of rejected manuscripts should disclose 
this practice in their Information for Authors. 
When a manuscript is published, journals should keep 
copies of the original submission, reviews, revisions, and 
correspondence for at least three years and possibly in per-
petuity, depending on local regulations, to help answer 
future questions about the work should they arise. 
Editors should not publish or publicize peer reviewers' 
comments without permission of the reviewer and author. 
If journal policy is to blind authors to reviewer identity and 
comments are not signed, that identity must not be re-
vealed to the author or anyone else without the reviewers' 
expressed written permission. 
Confidentiality may have to be breached if dishonesty 
or fraud is alleged, but editors should notify authors or 
reviewers if they intend to do so and confidentiality must 
otherwise be honored. 
b. Timeliness 
Editors should do all they can to ensure timely pro-
cessing of manuscripts with the resources available to them. 
If editors intend to publish a manuscript, they should at-
tempt to do so in a timely manner and any planned delays 
should be negotiated with the authors. If a journal has no 
intention of proceeding with a manuscript, editors should 
endeavor to reject the manuscript as soon as possible to 
allow authors to submit to a different journal. 
c. Peer Review 
Peer review is the critical assessment of manuscripts 
submitted to journals by experts who are usually not part 
of the editorial staff. Because unbiased, independent, crit-
ical assessment is an intrinsic part of all scholarly work, 
including scientific research, peer review is an important 
extension of the scientific process. 
The actual value of peer review is widely debated, but 
the process facilitates a fair hearing for a manuscript among 
members of the scientific community. More practically, it 
helps editors decide which manuscripts are suitable for 
their journals. Peer review ofren helps authors and editors 
improve the quality of reporting. 
www.icmje.org 
It is the responsibility of the journal to ensure that 
systems are in place for selection of appropriate reviewers. 
It is the responsibility of the editor to ensure that reviewers 
have access to all materials that may be relevant to the 
evaluation of the manuscript, including supplementary 
material for e-only publication, and to ensure that reviewer 
comments are properly assessed and interpreted in the con-
text of their declared conflicts of interest. 
A peer-reviewed journal is under no obligation to send 
submitted manuscripts for review, and under no obligation 
to follow reviewer recommendations, favorable or negative. 
The editor of a journal is ultimately responsible for the 
selection of all its content, and editorial decisions may be 
informed by issues unrelated to the quality of a manu-
script, such as suitability for the journal. An editor can reject 
any article at any time before publication, including after ac-
ceptance if concerns arise about the integrity of the work. 
Journals may differ in the number and kinds of man-
uscripts they send for review, the number and types of 
reviewers they seek for each manuscript, whether the review 
process is open or blinded, and other aspects of the review 
process. For this reason and as a service to authors, journals 
should publish a description of their peer-review process. 
Journals should notify reviewers of the ultimate deci-
sion to accept or reject a paper, and should acknowledge 
the contribution of peer reviewers to their journal. Editors 
are encouraged to share reviewers' comments with co-
reviewers of the same paper, so reviewers can learn from 
each other in the review process. 
As part of peer review, editors are encouraged to re-
view research protocols, plans for statistical analysis if sep-
arate from the protocol, and/or contracts associated with 
project-specific studies. Editors should encourage authors 
to make such documents publicly available at the time of 
or after publication, before accepting such studies for pub-
lication. Some journals may require public posting of these 
documents as a condition of acceptance for publication. 
Journal requirements for independent data analysis 
and for public data availability are in flux at the time of this 
revision, reflecting evolving views of the importance of data 
availability for pre- and post-publication peer review. Some 
journal editors currently request a statistical analysis of trial 
data by an independent biostatistician before accepting 
studies for publication. Others ask authors to say whether 
the study data are available to third parties to view and/or 
use/reanalyze, while still others encourage or require au-
thors to share their data with others for review or reanaly-
sis. Each journal should establish and publish their specific 
requirements for data analysis and post in a place that 
potential authors can easily access. 
Some people believe that true scientific peer review 
begins only on the date a paper is published. In char spirit, 
medical journals should have a mechanism for readers to 
submit comments, questions, or criticisms about published 
articles, and authors have a responsibility to respond 
appropriately and cooperate with any requests from the 
I rich4/za.i-aim/za.i-aim/zai44418/zai0001d18a. ! murkarv I 5=96 I 11/29/18 I 8:52 ! Art: I I 
Unauthorized reproduction of this article is prohibited. 
Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals 
journal for data or additional information should questions 
about the paper arise after publication (see Section III). 
ICMJE believes investigators have a duty to maintain 
the primary data and analytic procedures underpinning the 
published results for at least IO years. The ICMJE encour-
ages the preservation of these data in a data repository to 
ensure their longer-term availability. 
d. Integrity 
Editorial decisions should be based on the relevance of 
a manuscript to the journal and on the manuscript's orig-
inality, quality, and contribution to evidence about impor-
tant questions. Those decisions should not be influenced 
by commercial interests, personal relationships or agendas, 
or findings that are negative or that credibly challenge ac-
cepted wisdom. In addition, authors should submit for 
publication or otherwise make publicly available, and edi-
tors should not exclude from consideration for publication, 
studies with findings that are not statistically significant or 
that have inconclusive findings. Such studies may provide 
evidence that, combined with that from other studies 
through meta-analysis, might still help answer important 
questions, and a public record of such negative or incon-
clusive findings may prevent unwarranted replication of 
effort or otherwise be valuable for other researchers consid-
ering similar work. 
Journals should clearly state their appeals process and 
should have a system for responding to appeals and 
complaints. 
e. Journal Metrics 
The journal impact factor is widely misused as a proxy 
for research and journal quality and as a measure of the 
importance of specific research projects or the merits of 
individual researchers, including their suitability for hiring, 
promotion, tenure, prizes, or research funding. ICMJE rec-
ommer.ds that journals reduce the emphasis on impact factor 
as a single measure, but rather provide a range of article and 
journal metrics relevant to their readers and authors. 
3. Peer Reviewers 
Manuscripts submitted to journals are privileged com-
munications that are authors' private, confidential prop-
erty, and authors may be harmed by premature disclosure 
of any or all of a manuscript's details. 
Reviewers therefore should keep manuscripts and the 
information they contain strictly confidential. Reviewers 
must not publicly discuss authors' work and must not ap-
propriate authors' ideas before the manuscript is published. 
Reviewers must not retain the manuscript for their per-
sonal use and should destroy copies of manuscripts after 
submitting their reviews. 
Reviewers are expected to respond promptly to re-
quests to review and to submit reviews within the time 
agreed. Reviewers' comments should be constructive, hon-
est, and polite. 
Reviewers should declare their conflicts of interest and 
recuse themselves from the peer-review process if a conflict 
exists. 
D. Journal Owners and Editorial Freedom 
1. Journal Owners 
Owners and editors of medical journals share a com-
mon purpose, but they have different responsibilities, and 
sometimes those differences lead to conflicts. 
It is the responsibility of medical journal owners to 
appoint and dismiss editors. Owners should provide edi-
tors at the time of their appointment with a contract that 
clearly states their rights and duties, authority, the general 
terms of their appointment, and mechanisms for resolving 
conflict. The editor's performance may be assessed using 
mutually agreed-upon measures, including but not neces-
sarily limited to readership, manuscript submissions and 
handling times, and various journal metrics. 
Owners should only dismiss editors for substantial rea-
sons, such as scientific misconduct, disagreement with the 
long-term editorial direction of the journal, inadequate 
performance by agreed-upon performance metrics, or in-
appropriate behavior that is incompatible with a position 
of trust. 
Appointments and dismissals should be based on eval-
uations by a panel of independent experts, rather than by a 
small number of executives of the owning organization. 
This is especially necessary in the case of dismissals because 
of the high value society places on freedom of speech 
within science and because it is often the responsibility of 
editors to challenge the status quo in ways that may con-
flict with the interests of the journal's owners. 
A medical journal should explicitly state its governance 
and relationship to a journal owner (e.g., a sponsoring 
society). 
2. Editorial Freedom 
The ICMJE adopts the World Association of Medical 
Editors' definition of editorial freedom, which holds that 
editors-in-chief have full authority over the entire editorial 
content of their journal and the timing of publication of 
that content. Journal owners should not interfere in the 
evaluation, selection, scheduling, or editing of individual 
articles either directly or by creating an environment that 
strongly influences decisions. Editors should base editorial 
decisions on the validity of the work and its importance to 
the journal's readers, not on the commercial implications 
for the journal, and editors should be free to express critical 
but responsible views about all aspects of medicine without 
fear of retribution, even if these views conflict with the 
commercial goals of the publisher. 
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Editors-in-chief should also have the final say in deci-
sions about which advertisements or sponsored content, 
including supplements, the journal will and will not carry, 
and they should have final say in use of the journal brand 
and in overall policy regarding commercial use of journal 
content. 
Journals are encouraged to establish an independent 
editorial advisory board to help the editor establish and 
maintain editorial policy. Editors should seek to engage a 
broad and diverse array of authors, reviewers, editorial 
staff, editorial board members, and readers. To support 
editorial decisions and potentially controversial expressions 
of opinion, owners should ensure that appropriate insur-
ance is obtained in the event of legal action against the 
editors, and should ensure that legal advice is available 
when necessary. If legal problems arise, the editor should 
inform their legal adviser and their owner and/or publisher 
as soon as possible. Editors should defend the confidenti-
ality of authors and peer-reviewers (names and reviewer 
comments) in accordance with ICMJE policy (see Section 
II C.2.a). Editors should take all reasonable steps to check 
the facts in journal commentary, including that in news 
sections and social media postings, and should ensure that 
staff working for the journal adhere to best journalistic 
practices including contemporaneous note-taking and 
seeking a response from all parties when possible before 
publication. Such practices in support of truth and public 
interest may be particularly relevant in defense against legal 
allegations of libel. 
To secure editorial freedom in practice, the editor 
should have direct access to the highest level of ownership, 
not to a delegated manager or administrative officer. 
Editors and editors' organizations are obliged to sup-
port the concept of editorial freedom and to draw major 
transgressions of such freedom to the attention of the in-
ternational medical, academic, and lay communities. 
E. Protection of Research Participants 
All investigators should ensure that the planning con-
duct and reporting of human research are in accordance 
with the Helsinki Declaration as revised in 2013 
(www.wma.net/policies-postlwma-declaration-of-helsinki-
ethical-principles-for-medical-research-involving-human-
subjects/). All authors should seek approval to conduct 
research from an independent local, regional, or national 
review body (e.g., ethics committee, institutional review 
board). If doubt exists whether the research was conducted 
in accordance with the Helsinki Declaration, the authors 
must explain the rationale for their approach and demon-
strate that the local, regional, or national review body ex-
plicitly approved the doubtful aspects of the study. Ap-
proval by a responsible review body does not preclude 
editors from forming their own judgment whether the con-
duct of the research was appropriate. 
Patients have a right to privacy that should not be 
violated without informed consent. Identifying informa-
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tion, including names, initials, or hospital numbers, should 
not be published in written descriptions, photographs, or 
pedigrees unless the information is essential for scientific 
purposes and the patient (or parent or guardian) gives writ-
ten informed consent for publication. Informed consent 
for this purpose requires that an identifiable patient be 
shown the manuscript to be published. Authors should 
disclose to these patients whether any potential identifiable 
material might be available via the Internet as well as in 
print after publication. Patient consent should be written 
and archived with the journal, the authors, or both, as 
dictated by local regulations or laws. Applicable laws vary 
from locale to locale, and journals should establish their 
own policies with legal guidance. Since a journal that ar-
chives the consent will be aware of patient identity, some 
journals may decide that patient confidentiality is better 
guarded by having the author archive the consent and in-
stead providing the journal with a written statement that 
attests that they have received and archived written patient 
consent. 
Nonessential identifying details should be omitted. In-
formed consent should be obtained if there is any doubt 
that anonymity can be maintained. For example, masking 
the eye region in photographs of patients is inadequate 
protection of anonymity. If identifying characteristics are 
de-identified, authors should provide assurance, and edi-
tors should so note, that such changes do not distort sci-
entific meaning. 
The requirement for informed consent should be in-
cluded in the journal's instructions for authors. When in-
formed consent has been obtained, it should be indicated 
in the published article. 
When reporting experiments on animals, authors should 
indicate whether institutional and national standards for 
the care and use of laboratory animals were followed. Fur-
ther guidance on animal research ethics is available from 
the International Association of Veterinary Editors' Con-
sensus Author Guidelines on Animal Ethics and Welfare 
(http:/ /vetedi tors.erg/ ethicsconsensusguidelines .html). 
Ill. PUBLISHING AND EDITORIAL ISSUES RELATED TO 
PUBLICATION IN MEDICAL JOURNALS 
A. Corrections, Retractions, Republications, and Version 
Control 
Honest errors are a part of science and publishing and 
require publication of a correction when they are detected. 
Corrections are needed for errors of fact. Matters of debate 
are best handled as letters to the editor, as print or elec-
tronic correspondence, or as posts in a journal-sponsored 
online forum. Updates of previous publications (e.g., an 
updated systematic review or clinical guideline) are consid-
ered a new publication rather than a version of a previously 
published article. 
If a correction is needed, journals should follow these 
minimum standards: 
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• The journal should publish a correction notice as 
soon as possible detailing changes from and citing the orig-
inal publication; the correction should be on an electronic 
or numbered print page that is included in an electronic or 
a print Table of Contents to ensure proper indexing. 
• The journal should also post a new article version 
with details of the changes from the original version and 
the date(s) on which the changes were made. 
• The journal should archive all prior versions of the 
article. This archive can be either directly accessible to 
readers or can be made available to the reader on request. 
• Previous electronic versions should prominently 
note that there are more recent versions of the article. 
• The citation should be to the most recent version. 
Pervasive errors can result from a coding problem or a 
miscalculation and may result in extensive inaccuracies 
throughout an article. If such errors do not change the 
direction or significance of the results, interpretations, and 
conclusions of the article, a correction should be published 
that follows the minimum standards noted above. 
Errors serious enough to invalidate a paper's results 
and conclusions may require retraction . However, retrac-
tion with republication (also referred to as "replacement") 
can be considered in cases where honest error (e.g., a mis-
classification or miscalculation) leads to a major change in 
the direction or significance of the results, interpretations, 
and conclusions. If the error is judged to be unintentional, 
the underlying science appears valid, and the changed ver-
sion of the paper survives further review and editorial scru-
tiny, then retraction with republication of the changed pa-
per, with an explanation, allows full correction of the 
scientific literature. In such cases, it is helpful to show the 
extent of the changes in supplementary material or in an 
appendix, for complete transparency. 
B. Scientific Misconduct, Expressions of Concern, and 
Retraction 
Scientific misconduct in research and non-research 
publications includes but is not necessarily limited to data 
fabrication; data falsification, including deceptive manipu-
lation of images; purposeful failure to disclose conflicts of 
interest; and plagiarism. Some people consider failure to 
publish the results of clinical trials and other human stud-
ies a form of scientific misconduct. While each of these 
practices is problematic, they are not equivalent. Each sit-
uation requires individual assessment by relevant stake-
holders. When scientific misconduct is alleged, or concerns 
are otherwise raised about the conduct or integrity of work 
described in submitted or published papers, the editor should 
initiate appropriate procedures detailed by such commit-
tees as the Committee on Publication Ethics (COPE) (pub-
licationethics.org/resources/flowcharts), consider informing 
the institutions and funders, and may choose to publish an 
expression of concern pending the outcomes of those pro-
cedures. If the procedures involve an investigation at the 
authors' institution, the editor should seek to discover the 
outcome of that investigation; notify readers of the out-
come if appropriate; and if the investigation proves scien-
tific misconduct, publish a retraction of the article. There 
may be circumstances in which no misconduct is proven, 
but an exchange of letters to the editor could be published 
to highlight matters of debate to readers. 
Expressions of concern and retractions should not sim-
ply be a letter to the editor. Rather, they should be prom-
inently labelled, appear on an electronic or numbered print 
page that is included in an electronic or a print Table of 
Contents to ensure proper indexing, and include in their 
heading the tide of the original article. Online, the retrac-
tion and original article should be linked in both directions 
and the retracted article should be clearly labelled as re-
tracted in all its forms (abstract, full text, PDF). Ideally, the 
authors of the retraction should be the same as those of the 
article, but if they are unwilling or unable the editor may 
under certain circumstances accept retractions by other re-
sponsible persons, or the editor may be the sole author of 
the retraction or expression of concern. The text of the 
retraction should explain why the article is being retracted 
and include a complete citation reference to that article. 
Retracted articles should remain in the public domain and 
be clearly labelled as retracted. 
The validity of previous work by the author of a fraud-
ulent paper cannot be assumed. Editors may ask the au-
thor's institution to assure them of the validity of other 
work published in their journals, or they may retract it. If 
this is not done, editors may choose to publish an an-
nouncement expressing concern that the validity of previ-
ously published work is uncertain. 
The integrity of research may also be compromised by 
inappropriate methodology that could lead to retraction. 
See COPE flowcharts for further guidance on retrac-
tions and expressions of concern. See Section IV.g.i. for 
guidance about avoiding referencing retracted articles. 
C. Copyright 
Journals should make clear the type of copyright under 
which work will be published, and if the journal retains 
copyright, should detail the journal's position on the trans-
fer of copyright for all types of content, including audio, 
video, protocols, and data sets. Medical journals may ask 
authors to transfer copyright to the journal. Some journals 
require transfer of a publication license. Some journals do 
not require transfer of copyright and rely on such vehicles 
as Creative Commons licenses. The copyright status of ar-
ticles in a given journal can vary: Some content cannot be 
copyrighted (e.g., articles written by employees of some 
governments in the course of their work). Editors may 
waive copyright on other content, and some content may 
be protected under other agreements. 
D. Overlapping Publications 
1. Duplicate Submission 
Authors should not submit the same manuscript, in 
the same or different languages, simultaneously to more 
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than one journal. The rationale for this standard is the 
potential for disagreement when two (or more) journals 
claim the right to publish a manuscript that has been sub-
mitted simultaneously to more than one journal, and the 
possibility that two or more journals will unknowingly and 
unnecessarily undertake the work of peer review, edit the 
same manuscript, and publish the same article. 
2. Duplicate and Prior Publication 
Duplicate publication is publication of a paper that 
overlaps substantially with one already published, without 
clear, visible reference to the previous publication. Prior 
publication may include release of information in the pub-
lic domain. 
Readers of medical journals deserve to be able to trust 
that what they are reading is original unless there is a clear 
statement that the author and editor are intentionally re-
publishing an article (which might be considered for his-
toric or landmark papers, for example). The bases of this 
position are international copyright laws, ethical conduct, 
and cost-effective use of resources. Duplicate publication of 
original research is particularly problematic because it can 
result in inadvertent double-counting of data or inappro-
priate weighting of the results of a single study, which 
distorts the available evidence. 
When authors submit a manuscript reporting work 
that has already been reported in large part in a published 
article or is contained in or closely related to another paper 
that has been submitted or accepted for publication else-
where, the letter of submission should clearly say so and 
the authors should provide copies of the related material to 
help the editor decide how to handle the submission. See 
also Section IV.B. 
This recommendation does not prevent a journal from 
considering a complete report that follows publication of a 
preliminary report, such as a letter to the editor, a preprint, 
or an abstract or poster displayed at a scientific meeting. It 
also does not prevent journals from considering a paper 
that has been presented at a scientific meeting but was not 
published in full, or that is being considered for publica-
tion in proceedings or similar format. Press reports of 
scheduled meetings are not usually regarded as breaches of 
this rule, but they may be if additional data tables or fig-
ures enrich such reports. Authors should also consider how 
dissemination of their findings outside of scientific presen-
tations at meetings may diminish the priority journal edi-
tors assign to their work. 
Authors who choose to post their work on a preprint 
server should choose one that clearly identifies preprints as 
not peer-reviewed work and includes statements of con-
flicts of interest. It is the author's responsibility to inform a 
journal if the work has been previously posted on a 
preprint server. In addition, it is the author's (and not the 
journal editors') responsibility to ensure that preprints are 
www.icmje.org 
amended to point readers to subsequent versions, including 
the final published article. 
In the event of a public health emergency (as defined 
by public health officials), information with immediate im-
plications for public health should be disseminated without 
concern that this will preclude subsequent consideration 
for publication in a journal. We encourage editors to give 
priority to authors who have made crucial data publicly 
available (e.g., in a gene bank) without delay. 
Sharing with public media, government agencies, or 
manufacturers the scientific information described in a pa-
per or a letter to the editor that has been accepted but not 
yet published violates the policies of many journals. Such 
reporting may be warranted when the paper or letter de-
scribes major therapeutic advances; reportable diseases; or 
public health hazards, such as serious adverse effects of 
drugs, vaccines, other biological products, medical de-
vices. This reporting, whether in print or online, should 
not jeopardize publication, but should be discussed 
with and agreed upon by the editor in advance when 
possible. 
The ICMJE will not consider as prior publication the 
posting of trial results in any registry that meets the criteria 
noted in Section III.L. if results are limited to a brief (500 
word) structured abstract or tables (to include participants 
enrolled, key outcomes, and adverse events). The ICMJE 
encourages authors to include a statement with the regis-
tration that indicates that the results have not yet been 
published in a peer-reviewed journal, and to update the 
results registry with the full journal citation when the re-
sults are published. 
Editors of different journals may together decide to 
simultaneously or jointly publish an article if they believe 
that doing so would be in the best interest of public health. 
However, the National Library of Medicine (NLM) in-
dexes all such simultaneously published joint publications 
separately, so editors should include a statement making 
the simultaneous publication clear to readers. 
Authors who attempt duplicate publication without 
such notification should expect at least prompt rejection of 
the submitted manuscript. If the editor was not aware 
of the violations and the article has already been published, 
then the article might warrant retraction with or without 
the author's explanation or approval. 
See COPE flowcharts for further guidance on han-
dling duplicate publication. 
3. Acceptable Secondary Publication 
Secondary publication of material published in other 
journals or online may be justifiable a~d beneficial, espe-
cially when intended to disseminate important information 
to the widest possible audience (e.g., guidelines produced 
by government agencies and professional organizations in 
the same or a different language). Secondary publication 
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for various other reasons may also be justifiable provided 
the following conditions are met: 
1. The authors have received approval from the edi-
tors of both journals (the editor concerned with secondary 
publication must have access to the primary version). 
2. The priority of the primary publication is respected 
by a publication interval negotiated by both editors with 
the authors. 
3. The paper for secondary publication is intended for 
a different group of readers; an abbreviated version could 
be sufficient. 
4. The secondary version faithfully reflects the data 
and interpretations of the primary version. 
5. The secondary version informs readers, peers, and 
documenting agencies that the paper has been published in 
whole or in part elsewhere-for example, with a note that 
might read, "This article is based on a study first reported 
in the [journal title, with full reference]"-and the second-
ary version cites the primary reference. 
6. The tide of the secondary publication should indi-
cate that it is a secondary publication (complete or 
abridged republication or translation) of a primary publi-
cation. Of note, the NLM does not consider translations to 
be "republications" and does not cite or index them when 
the original article was published in a journal that is in-
dexed in MEDLINE. 
When the same journal simultaneously publishes an 
article in multiple languages, the MEDLINE citation will 
note the multiple languages (e.g., Angelo M. Journal net-
working in nursing: a challenge to be shared. Rev Esc En-
ferm USP. 2011 Dec 45[6]:1281-2,1279-80,1283-4. Arti-
cle in English, Portuguese, and Spanish. No abstract 
available. PMID 22241182). 
4. Manuscripts Based on the Same Database 
If editors receive manuscripts from separate research 
groups or from the same group analyzing the same data set 
(e.g., from a public database, or systematic reviews or 
meta-analyses of the same evidence), the manuscripts 
should be considered independently because they may dif-
fer in their analytic methods, conclusions, or both. If the 
data interpretation and conclusions are similar, it may be 
reasonable although not mandatory for editors to give pref-
erence to the manuscript submitted first. Editors might 
consider publishing more than one manuscript that overlap 
in this way because different analytical approaches may be 
complementary and equally valid, but manuscripts based 
upon the same dataset should add substantially to each 
other to warrant consideration for publication as separate 
papers, with appropriate citation of previous publications 
from the same dataset to allow for transparency. 
Secondary analyses of clinical trial data should cite any 
primary publication, clearly state that it contains secondary 
analyses/results, and use the same identifying trial registra-
101 
tion number as the primary trial and umque, persistent 
dataset identifier. 
Sometimes for large trials it is planned from the be-
ginning to produce numerous separate publications regard-
ing separate research questions but using the same original 
participant sample. In this case authors may use the origi-
nal single trial registration number, if all the outcome pa-
rameters were defined in the original registration. If the 
authors registered several substudies as separate entries in, 
for example, clinicaltrials.gov, then the unique trial identi-
fier should be given for the study in question, The main 
issue is transparency, so no matter what model is used it 
should be obvious for the reader. 
E. Correspondence 
Medical journals should provide readers with a mech-
anism for submitting comments, questions, or criticisms 
about published articles, usually but not necessarily always 
through a correspondence section or online forum . The 
authors of articles discussed in correspondence or an online 
forum have a responsibility to respond to substantial criti-
cisms of their work using those same mechanisms and 
should be asked by editors to respond. Authors of corre-
spondence should be asked to declare any competing or 
conflicting interests. 
Correspondence may be edited for length, grammati-
cal correctness, and journal style. Alternatively, editors may 
choose to make available to readers unedited correspon-
dence, for example, via an online commenting system. 
Such commenting is not indexed in Medline unless it is 
subsequently published on a numbered electronic or print 
page. However the journal handles correspondence, it 
should make known its practice. In all instances, editors 
must make an effort to screen discourteous, inaccurate, or 
libellous comments. 
Responsible debate, critique, and disagreement are im-
portant features of science, and journal editors should en-
courage such discourse ideally within their own journals 
about the material they have published. Editors, however, 
have the prerogative to reject correspondence that is irrel-
evant, uninteresting, or lacking cogency, but they also have 
a responsibility to allow a range of opinions to be expressed 
and to promote debate. 
In the interests of fairness and to keep correspondence 
within manageable proportions, journals may want to set 
time limits for responding to published material and for 
debate on a given topic. 
F. Fees 
Journals should be transparent about their types of 
revenue streams. Any fees or charges that are required for 
manuscript processing and/or publishing materials in the 
journal shall be clearly stated in a place that is easy for 
potential authors to find prior to submitting their manu-
scripts for review or explained to authors before they begin 
preparing their manuscript for submission (http://publica 
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tionethics.org/files/u7140/Principles_of_ Transparency _and_ 
Best_Practice_in_Scholarly _Publishing. pdf). 
G. Supplements, Theme Issues, and Special Series 
Supplements are collections of papers that deal with 
related issues or topics, are published as a separate issue of 
the journal or as part of a regular issue, and may be funded 
by sources other than the journal's publisher. Because 
funding sources can bias the content of supplements 
through the choice of topics and viewpoints, journals 
should adopt the following principles, which also apply to 
theme issues or special series that have external funding 
and/or guest editors: 
1. The journal editor must be given and must take 
full responsibility for the policies, practices, and content of 
supplements, including complete control of the decision to 
select authors, peer reviewers, and content for the supple-
ment. Editing by the funding organization should not be 
permitted. 
2. The journal editor has the right to appoint one or 
more external editors of the supplement and must take 
responsibility for the work of those editors. 
3. The journal editor must retain the authority to 
send supplement manuscripts for external peer review and 
to reject manuscripts submitted for the supplement with or 
without external review. These conditions should be made 
known to authors and any external editors of the supple-
ment before beginning editorial work on it. 
4. The source of the idea for the supplement, sources 
of funding for the supplement's research and publication, 
and products of the funding source related to content con-
sidered in the supplement should be clearly stated in the 
introductory material. 
5. Advertising in supplements should follow the same 
policies as those of the primary journal. 
6. Journal editors must enable readers to distinguish 
readily between ordinary editorial pages and supplement 
pages. 
7. Journal and supplement editors must not accept 
personal favors or direct remuneration from sponsors of 
supplements. 
8. Secondary publication in supplements (republica-
tion of papers published elsewhere) should be clearly iden-
tified by the citation of the original paper and by the tide. 
9. The same principles of authorship and disclosure of 
potential conflicts of interest discussed elsewhere in this 
document should be applied to supplements. 
H. Sponsorship or Partnership 
Various entities may seek interactions with journals or 
editors in the form of sponsorships, partnerships, meetings, 
or other types of activities. To preserve editorial indepen-
dence, these interactions should be governed by the same 
principles outlined above for Supplements, Theme Issues, 
and Special Series (Section III.G). 
www.icmje.org 
I. Electronic Publishing 
Most medical journals are now published in electronic 
as well as print versions, and some are published only in 
electronic form. Principles of print and electronic publish-
ing are identical, and the recommendations of this docu-
ment apply equally to both. However, electronic publish-
ing provides opportunities for versioning and raises issues 
about link stability and content preservation that are ad-
dressed here. 
Recommendations for corrections and versioning are 
detailed in Section III.A. 
Electronic publishing allows linking to sites and re-
sources beyond journals over which journal editors have no 
editorial control. For this reason, and because links to ex-
ternal sites could be perceived as implying endorsement of 
those sites, journals should be cautious about external link-
ing. When a journal does link to an external site, it should 
state that it does not endorse or take responsibility or lia-
bility for any content, advertising, products, or other ma-
terials on the linked sites, and does not take responsibility 
for the sites' availability. 
Permanent preservation of journal articles on a jour-
nal's website, or in an independent archive or a credible 
repository, is essential for the historical record. Removing 
an article from a journal's website in its entirety is almost 
never justified as copies of the article may have been down-
loaded even if its online posting was brief. Such archives 
should be freely accessible or accessible to archive mem-
bers. Deposition in multiple archives is encouraged. How-
ever, if necessary for legal reasons (e.g., Jibe! action), the 
URL for the removed article must contain a detailed reason 
for the removal, and the article must be retained in the 
journal's internal archive. 
Permanent preservation of a journal's total content is 
the responsibility of the journal publisher, who in the event 
of journal termination should be certain the journal files 
are transferred to a responsible third party who can make 
the content available. 
Journal websites should post the date that nonarticle 
web pages, such as those listing journal staff, editorial 
board members, and instructions for authors, were last up-
dated. 
J. Advertising 
Most medical journals carry advertising, which gener-
ates income for their publishers, but journals should not be 
dominated by advertisements, and advertising must not be 
allowed to influence editorial decisions. 
Journals should have formal, explicit, written policies 
for advertising in both print and electronic versions. Best 
practice prohibits selling advertisements intended to be 
juxtaposed with editorial content on the same product. 
Advertisements should be clearly identifiable as advertise-
ments. Editors should have full and final authority for ap-
proving print and online advertisements and for enforcing 
advertising policy. 
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Journals should not carry advertisements for products 
proven to be seriously harmful to health. Editors should 
ensure that existing regulatory or industry standards for 
advertisements specific to their country are enforced, or 
develop their own standards. The interests of organizations 
or agencies should not control classified and other nondis-
play advertising, except where required by law. Editors 
should consider all criticisms of advertisements for publi-
cation. 
K. Journals and the Media 
Journals' interactions with media should balance com-
peting priorities. The general public has a legitimate inter-
est in all journal content and is entitled to important in-
formation within a reasonable amount of time, and editors 
have a responsibility to facilitate that. However media re-
ports of scientific research before it has been peer-reviewed 
and fully vetted may lead to dissemination of inaccurate or 
premature conclusions, and doctors in practice need to 
have research reports available in full detail before they can 
advise patients about the reports' conclusions. 
An embargo system has been established in some 
countries and by some journals to assist this balance, and 
to prevent publication of stories in the general media be-
fore publication of the original research in the journal. For 
the media, the embargo creates a "level playing field," 
which most reporters and writers appreciate since it mini-
mizes the pressure on them to publish stories before com-
petitors when they have not had time to prepare carefully. 
Consistency in the timing of public release of biomedical 
information is also important in minimizing economic 
chaos, since some articles contain information that has 
potential to influence financial markets. The ICMJE ac-
knowledges criticisms of embargo systems as being self-
serving of journals' interests and an impediment to rapid 
dissemination of scientific information, but believe the 
benefits of the systems outweigh their harms. 
The following principles apply equally to print and 
electronic publishing and may be useful to editors as they 
seek to establish policies on interactions with the media: 
• Editors can foster the orderly transmission of med-
ical information from researchers, through peer-reviewed 
journals, to the public. This can be accomplished by an 
agreement with authors that they will not publicize their 
work while their manuscript is under consideration or 
awaiting publication and an agreement with the media that 
they will not release stories before publication of the orig-
inal research in the journal, in return for which the journal 
will cooperate with them in preparing accurate stories by 
issuing, for example, a press release. 
• Editors need to keep in mind that an embargo sys-
tem works on the honor system-no formal enforcement 
or policing mechanism exists. The decision of a significant 
number of media outlets or biomedical journals not to respect 
the embargo system would lead to its rapid dissolution. 
121 
• Notwithstanding authors' belief in their work, very 
little medical research has such clear and urgently impor-
tant clinical implications for the public's health that the 
news must be released before full publication in a journal. 
When such exceptional circumstances occur, the appropri-
ate authorities responsible for public health should decide 
whether to disseminate information to physicians and the 
media in advance and should be responsible for this decision. 
If the author and the appropriate authorities wish to have a 
manuscript considered by a particular journal, the editor 
should be consulted before any public release. If editors ac-
knowledge the need for immediate release, they should waive 
their policies limiting prepublication publicity. 
• Policies designed to limit prepublication publicity 
should not apply to accounts in the media of presentations 
at scientific meetings or to the abstracts from these meet-
ings (see Duplicate Publication). Researchers who present 
their work at a scientific meeting should feel free to discuss 
their presentations with reporters but should be discour-
aged from offering more detail about their study than was 
presented in the talk, or should consider how giving such 
detail might diminish the priority journal editors assign to 
their work (see Duplicate Publication). 
• When an article is close to being published, editors 
or journal staff should help the media prepare accurate 
reports by providing news releases, answering questions, 
supplying advance copies of the article, or referring report-
ers to appropriate experts. This assistance should be con-
tingent on the media's cooperation in timing the release of 
a story to coincide with publication of the article. 
L. Clinical Trials 
i. Registration 
The ICMJE's clinical trial registration policy is detailed in 
a series of editorials (see Updates and Editorials [www.icmje 
.org/news-and-editorials/] and FAQs [www.icmje.org/about-
icmje/faqs/]). 
Briefly, the ICMJE requires, and recommends that all 
medical journal editors require, registration of clinical trials 
in a public trials registry at or before the time of first 
patient enrollment as a condition of consideration for pub-
lication. Editors requesting inclusion of their journal on 
the ICMJE website list of publications that follow ICMJE 
guidance [icmje.org/journals.html] should recognize that 
the listing implies enforcement by the journal of ICMJE's 
trial registration policy. 
ICMJE uses the date trial registration materials were 
first submitted to a registry as the date of registration. 
When there is a substantial delay between the submission 
of registration materials and their posting at the trial reg-
istry, editors may inquire about the circumstances that led 
to the delay. 
The ICMJE defines a clinical trial as any research proj-
ect that prospectively assigns people or a group of people to 
an intervention, with or without concurrent comparison or 
control groups, to study the relationship between a health-
www.icmje.org 
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related intervention and a health outcome. Health-related 
interventions are those used to modify a biomedical or 
health-related outcome; examples include drugs, surgical 
procedures, devices, behavioral treatments, educational 
programs, dietary interventions, quality improvement in-
terventions, and process-of-care changes. Health outcomes 
are any biomedical or health-related measures obtained in 
patients or participants, including pharmacokinetic mea-
sures and adverse events. The ICMJE does not define the 
timing of first participant enrollment, but best practice dic-
tates registration by the time of first participant consent. 
The ICMJE accepts publicly accessible registration 
in any registry that is a primary register of the WHO 
International Clinical Trials Registry Platform (ICTRP) 
(www.who.int/ictrp/network/primary/en/index.html) or 
in ClinicalTrials.gov, which is a data provider to the 
WHO ICTRP. The ICMJE endorses these registries be-
cause they meet several criteria. They are accessible to 
the public at no charge, open to all prospective regis-
trants, managed by a not-for-profit organization, have a 
mechanism to ensure the validity of the registration 
data, and are electronically searchable. An acceptable 
registry must include the minimum 21 item trial re-
gistration dataset (http:/ /prsinfo.clinicaltrials.gov!train 
T rainer/WH O-I CMJE-Clin T rialsgov-Cross-Ref.pdf or www 
.who.int/ictrp/network/trds/en/index.html) at the time of 
registration and before enrollment of the first participant. 
The ICMJE considers inadequate trial registrations missing 
any of the 21 data fields, those that have fields that contain 
uninformative information, or registrations that are not 
made publicly accessible such as phase I trials submitted to 
the EU-CTR and trials of devices for which the informa-
tion is placed in a "lock box." In order to comply with 
ICMJE policy, investigators registering trials of devices at 
ClinicalTrials.gov must "opt out" of the lock box by elect-
ing public posting prior to device approval. Although not a 
required item, the ICMJE encourages authors to include a 
statement that indicates that the results have not yet been 
published in a peer-reviewed journal, and to update the 
registration with the full journal citation when the results 
are published. 
The purpose of clinical trial registration is to prevent 
selective publication and selective reporting of research 
outcomes, to prevent unnecessary duplication of research 
effort, to help patients and the public know what trials are 
planned or ongoing into which they might want to enroll, 
and to help give ethics review boards considering approval 
of new studies a view of similar work and data relevant to 
the research they are considering. Retrospective registra-
tion, for example at the time of manuscript submission, 
meets none of these purposes. Those purposes apply also to 
research with alternative designs, for example observational 
studies. For that reason, the ICMJE encourages registration 
of research with non-trial designs, but because the exposure 
or intervention in non-trial research is not dictated by the 
researchers, the ICMJE does not require it. 
www.icmje.org 
Secondary data analyses of primary (parent) clinical 
trials should not be registered as separate clinical trials, but 
instead should reference the trial registration number of 
the primary trial. 
The ICMJE expects authors to ensure that they have 
met the requirements of their funding and regulatory agen-
cies regarding aggregate clinical trial results reporting in 
clinical trial registries. It is the authors', and not the journal 
editors', responsibility to explain any discrepancies between 
results reported in registries and journal publications. The 
ICMJE will not consider as prior publication the posting 
of trial results in any registry that meets the above criteria if 
results are limited to a brief (500 word) structured abstract 
or tables (to include trial participants enrolled, baseline 
characteristics, primary and secondary outcomes, and ad-
verse events). 
The ICMJE recommends that journals publish the 
trial registration number at the end of the abstract. The 
ICMJE also recommends that, whenever a registration 
number is available, authors list this number the first time 
they use a trial acronym to refer either to the trial they 
are reporting or to other trials that they mention in the 
manuscript. 
Editors may consider whether the circumstances in-
volved in a failure to appropriately register a clinical trial 
were likely to have been intended to or resulted in biased 
reporting. Because of the importance of prospective trial 
registration, if an exception to this policy is made, trials 
must be registered and the authors should indicate in the 
publication when registration was completed and why it 
was delayed. Editors should publish a statement indicating 
why an exception was allowed. The ICMJE emphasizes 
that such exceptions should be rare, and that authors fail-
ing to prospectively register a trial risk its inadmissibililty 
to our journals. 
ii. Data Sharing 
The ICMJE's data sharing statement policy is 
detailed in an editorial (see Updaces and Editorials 
[ www.icmje.org/update.html]) . 
1. As of 1 July 2018 manuscripts submitted to ICMJE 
journals that report the results of clinical trials must con-
tain a data sharing statement as described below. 
2. Clinical trials that begin enrolling participants on or 
after 1 January 2019 must include a data sharing plan in the 
trial's registration. The ICMJE's policy regarding trial registra-
tion is explained at www.icmje.org/recommendations/browse/ 
publishing-and-editorial-issues/clinical-trial-registration.html. 
If the data sharing plan changes after registration this 
should be reflected in the statement submitted and pub-
lished with the manuscript, and updated in the registry 
record. 
Data sharing statements must indicate the following: 
whether individual deidentified participant data (including 
data dictionaries) will be shared ("undecided" 1s not an 
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Table. Examples of Data Sharing Statements That Fulfill These ICMJE Requirements* 
Will individual participant 
data be available 
(including data 
dictionaries)? 
What data in particular 
will be shared? 
What other documents 
will be available? 
When will data be 
available (start and 
end dates)? 
With whom? 
For what types of 
analyses? 
By what mechanism will 
data be made 
available? 
Example 1 
Yes 
All of the individual 
participant data collected 
during the trial, after 
deidentification. 
Study Protocol, Statistical 
Analysis Plan, Informed 
Consent Form, Clinical 
Study Report, Analytic 
Code 
Immediately following 
publication. No end date. 
Anyone who wishes to access 
the data. 
Any purpose. 
Data are available indefinitely 
at (Link to be included) . 
Example 2 
Yes 
Individual participant data 
that underlie the results 
reported in this article, 
after deidentification 
(text, tables, figures, 
and appendices). 
Study Protocol, Statistical 
Analysis Plan, Analytic 
Code 
Beginning 3 months and 
ending 5 years 
following article 
publication. 
Researchers who provide 
a methodologically 
sound proposal. 
To achieve aims in the 
approved proposal. 
Proposals should be 
directed to xxx@yyy. 
To gain access, data 
requestors will need to 
sign a data access 
agreement. Data are 
available for 5 years at 
a third party website 
(Link to be included). 
* These examples are meanr to illustrate a range of, but not all, data sharing options. 
Example 3 
Yes 
Individual participant data that 
underlie the results reported 
in this article, after 
deidentification (text, tables, 
figures, and appendices). 
Study Protocol 
Beginning 9 months and 
ending 36 months following 
article publication . 
Investigators whose proposed 
use of the data has been 
approved by an 
independent review 
committee (learned 
intermediary) identified for 
this purpose. 
For individual participant data 
meta-analysis. 
Proposals may be submitted 
up to 36 months following 
article publication . After 36 
months the data will be 
available in our University's 
data warehouse but without 
investigator support other 
than deposited metadata. 
Information regarding 
submitting proposals and 
accessing data may be 
found at (Link to be 
provided) . 
Example 4 
No 
Not available 
Not available 
Not applicable 
Not applicable 
Not applicable 
Not applicable 
acceptable answer); what data in particular will be shared; 
whether additional, related documents will be availabie 
(e.g., study protocol, statistical analysis plan, etc.); when 
the data will become available and for how long; by what 
access criteria data will be shared (including with whom, 
for what types of analyses, and by what mechanism). Illus-
trative examples of data sharing statements that would 
meet these requirements are provided in the Table. 
should seek collaboration with those who collected the 
data. As collaboration will not aiways be possible, practicai, 
or desired, the efforts of those who generated the data must 
be recognized. 
Authors of secondary analyses using shared data must 
attest that their use was in accordance with the terms (if 
any) agreed to upon their receipt. They must also reference 
the source of the data using its unique, persistent identifier 
to provide appropriate credit to those who generated it and 
allow searching for the studies it has supported. Authors of 
secondary analyses must explain completely how theirs dif-
fer from previous analyses. In addition, those who generate 
and then share clinical trial data sets deserve substantial 
credit for their efforts. Those using data collected by others 
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IV. MANUSCRIPT PREPARATION AND SUBMISSION 
A. Preparing a Manuscript for Submission to a Medical 
Journal 
1. General Principles 
The text of articles reporting original research is usu-
ally divided into Introduction, Methods, Results, and Dis-
cussion sections. This so-called "IMRAD" structure is not 
an arbitrary publication format but a reflection of the pro-
cess of scientific discovery. Articles often need subheadings 
within these sections to further organize their content. 
Other types of articles, such as meta-analyses, may require 
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different formats, while case reports, narrative reviews, and 
editorials may have less structured or unstructured formats. 
Electronic formats have created opportunities for add-
ing details or sections, layering information, cross-linking, 
or extracting portions of articles in electronic versions. 
Supplementary electronic-only material should be submit-
ted and sent for peer review simultaneously with the pri-
mary manuscript. 
2. Reporting Guidelines 
Reporting guidelines have been developed for different 
study designs; examples include CONSORT (www.consort 
-statement.org) for randomized trials, STROBE for obser-
vational studies (http:/ /strobe-statement.org/), PRIS MA 
for systematic reviews and meta-analyses (http://prisma 
-statement.org/), and STARD for studies of diagnostic 
accuracy (www.stard-statement.org/). Journals are encour-
aged to ask authors to follow these guidelines because they 
help authors describe the study in enough detail for it to 
be evaluated by editors, reviewers, readers, and other re-
searchers evaluating the medical literature. Authors of re-
view manuscripts are encouraged to describe the methods 
used for locating, selecting, extracting, and synthesizing 
data; this is mandatory for systematic reviews. Good 
sources for reporting guidelines are the EQUATOR Net-
work (www.equator-network.org/home/) and the NLM's 
Research Reporting Guidelines and Initiatives (www.nlm 
. nih. gov/ services/ research_report_guide. h rm!). 
3. Manuscript Sections 
The following are general requirements for reporting 
within sections of all study designs and manuscript formats. 
a. Title Page 
General information about an article and its authors 
is presented on a manuscript tide page and usually in-
cludes the article tide, author information, any disclaimers, 
sources of support, word count, and sometimes the num-
ber of tables and figures. 
Article title. The tide provides a distilled description 
of the complete article and should include information 
that, along with the abstract, will make electronic re-
trieval of the article sensitive and specific. Reporting 
guidelines recommend and some journals require that 
information about the study design be a part of the tide 
(particularly important for randomized trials and sys-
tematic reviews and meta-analyses). Some journals re-
quire a short title, usually no more than 40 characters 
(including letters and spaces) on the tide page or as a 
separate entry in an electronic submission system. Elec-
tronic submission systems may restrict the number of 
characters in the tide. 
Author information. Each author's highest academic 
degrees should be listed, although some journals do not 
publish these. The name of the department(s) and institu-
www.icmje.org 
tion(s) or organizations where the work should be attrib-
uted should be specified. Most electronic submission sys-
tems require that authors provide full contact information, 
including land mail and e-mail addresses, but the tide page 
should list the corresponding authors' telephone and fax 
numbers and e-mail address. ICMJE encourages the listing 
of authors' Open Researcher and Contributor Identifica-
tion (ORCID). 
Disclaimers. An example of a disclaimer is an author's 
statement that the views expressed in the submitted article 
are his or her own and not an official position of the insti-
tution or funder. 
Source(s) of support. These include grants, equipment, 
drugs, and/or other support that facilitated conduct of the 
work described in the article or the writing of the article 
itself. 
Word count. A word count for the paper's text, exclud-
ing its abstract, acknowledgments, tables, figure legends, 
and references, allows editors and reviewers to assess 
whether the information contained in the paper warrants 
the paper's length, and whether the submitted manuscript 
fits within the journal's formats and word limits. A separate 
word count for the abstract is useful for the same reason. 
Number of figures and tables. Some submission systems 
require specification of the number of figures and tables 
before uploading the relevant files . These numbers allow 
editorial staff and reviewers to confirm that all figures and 
tables were actually included with the manuscript and, 
because tables and figures occupy space, to assess if the 
information provided by the figures and tables warrants the 
paper's length and if the manuscript fits within the jour-
nal's space limits. 
Conflict of interest declaration. Conflict of interest in-
formation for each author needs to be part of the manu-
script; each journal should develop standards with regard 
to the form the information should take and where it will 
be posted. The ICMJE has developed a uniform conflict of 
interest disclosure form for use by ICMJE member jour-
nals (www.icmje.org/coi_disclosure.pdf), and the ICMJE 
encourages other journais to adopt it. Despite availability 
of the form, editors may require conflict of interest decla-
rations on the manuscript tide page to save the work of 
collecting forms from each author prior to making an ed-
itorial decision or to save reviewers and readers the work of 
reading each author's form. 
b. Abstract 
Original research, systematic reviews, and meta-
analyses require structured abstracts. The abstract should 
provide the context or background for the study and should 
state the study's purpose, basic procedures (selection of 
study participants, settings, measurements, analytical 
methods), main findings (giving specific effect sizes and 
their statistical and clinical significance, if possible), and 
principal conclusions. It should emphasize new and impor-
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tam aspects of the study or observations, note important 
limitations, and not overinterpret findings. Clinical trial 
abstracts should include items that the CONSORT group 
has identified as essential (www.consort-statement.org 
I resources/ downloads/extensions/consort-extension-for 
-abstracts-2008pdf/). Funding sources should be listed sep-
arately after the abstract to facilitate proper display and 
indexing for search retrieval by MEDLINE. 
Because abstracts are the only substantive portion of 
the article indexed in many electronic databases, and the 
only portion many readers read, authors need to ensure 
that they accurately reflect the content of the article. Un-
fortunately, information in abstracts often differs from that 
in the text. Authors and editors should work in the process 
of revision and review to ensure that information is consis-
tent in both places. The format required for structured 
abstracts differs from journal to journal, and some journals 
use more than one format; authors need to prepare their 
abstracts in the format specified by the journal they have 
chosen. 
The ICMJE recommends that journals publish the 
clinical trial registration number at the end of the ab-
stract. The ICMJE also recommends that, when a reg-
istration number is available, authors list that number 
the first time they use a trial acronym to refer to the trial 
they are reporting or to other trials that they mention in 
the manuscript. If the data have been deposited in a 
public repository and/or are being used in a secondary 
analysis, authors should state at the end of the abstract 
the unique, persistent data set identifier; repository 
name; and number. 
c. Introduction 
Provide a context or background for the study (that is, 
the nature of the problem and its significance). State the 
specific purpose or research objective of, or hypothesis 
tested by, the study or observation. Cite only directly per-
tinent references, and do not include data or conclusions 
from the work being reported. 
d. Methods 
The guiding principle of the Methods section should 
be clarity about how and why a study was done in a par-
ticular way. The Methods section should aim to be suffi-
ciently detailed such that others with access to the data 
would be able to reproduce the results. In general, the 
section should include only information that was available 
at the time the plan or protocol for the study was being 
written; all information obtained during the study belongs 
in the Results section. If an organization was paid or oth-
erwise contracted to help conduct the research (examples 
include data collection and management), then this should 
be detailed in the methods. 
The Methods section should include a statement indi-
cating that the research was approved by an independent 
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local, regional or national review body (e.g., ethics com-
mittee, institutional review board). If doubt exists whether 
the research was conducted in accordance with the Hel-
sinki Declaration, the authors must explain the rationale 
for their approach and demonstrate that the local, regional 
or national review body explicitly approved the doubtful 
aspects of the study. See Section II .E. 
i. Selection and Description of Participants 
Clearly describe the selection of observational or ex-
perimental participants (healthy individuals or patients, in-
cluding controls), including eligibility and exclusion crite-
ria and a description of the source population. Because the 
relevance of such variables as age, sex, or ethnicity is not 
always known at the time of study design, researchers 
should aim for inclusion of representative populations into 
all study types and at a minimum provide descriptive data 
for these and other relevant demographic variables. Ensure 
correct use of the terms sex (when reporting biological 
factors) and gender (identity, psychosocial or cultural fac-
tors), and, unless inappropriate, report the sex and/or gen-
der of study participants, the sex of animals or cells, and 
describe the methods used to determine sex and gender. If 
the study was done involving an exclusive population, for 
example in only one sex, authors should justify why, except 
in obvious cases (e.g. , prostate cancer) . Authors should de-
fine how they determined race or ethnicity and justify their 
relevance. Authors should use neutral, precise, and respect-
ful language to describe study participants and avoid the 
use of terminology that might stigmatize participants. 
ii. Technical Information 
Specify the study's main and secondary objectives-
usually identified as primary and secondary outcomes. 
Identify methods, equipment (give the manufacturer's 
name and address in parentheses), and procedures in suffi-
cient detail to allow others to reproduce the results. Give 
references to established methods, including statistical 
methods (see below); provide references and brief descrip-
tions for methods that have been published but are not 
well-known; describe new or substantially modified meth-
ods, give the reasons for using them, and evaluate their 
limitations. Identify precisely all drugs and chemicals used, 
including generic name(s), dose(s), and route(s) of admin-
istration. Identify appropriate scientific names and gene 
names. 
iii. Statistics 
Describe statistical methods with enough detail to en-
able a knowledgeable reader with access to the original data 
to judge its appropriateness for the study and to verify the 
reported results. When possible, quantify findings and 
present them with appropriate indicators of measurement 
error or uncertainty (such as confidence intervals). Avoid 
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relying solely on statistical hypothesis testing, such as P 
values, which fail to convey important information about 
effect size and precision of estimates. References for the 
design of the study and statistical methods should be to 
standard works when possible (with pages stated). Define 
statistical terms, abbreviations, and most symbols. Specify 
the statistical software package(s) and versions used. Dis-
tinguish prespecified from exploratory analyses, including 
subgroup analyses. 
e. Results 
Present your results in logical sequence in the text, 
tables, and figures, giving the main or most important 
findings first. Do not repeat all the data in the tables or 
figures in the text; emphasize or summarize only the most 
important observations. Provide data on all primary and 
secondary outcomes identified in the Methods section. Ex-
tra or supplementary materials and technical details can be 
placed in an appendix where they will be accessible but will 
not interrupt the flow of the text, or they can be published 
solely in the electronic version of the journal. 
Give numeric results not only as derivatives (e.g., per-
centages) but also as the absolute numbers from which the 
derivatives were calculated, and specify the statistical sig-
nificance attached to them, if any. Restrict tables and fig-
ures to those needed to explain the argument of the paper 
and to assess supporting data. Use graphs as an alternative 
to tables with many entries; do not duplicate data in 
graphs and tables. Avoid nontechnical uses of technical 
terms in statistics, such as "random" {which implies a 
randomizing device), "normal," "significant," "correla-
tions," and "sample." 
Separate reporting of data by demographic variables, 
such as age and sex, facilitate pooling of data for subgroups 
across studies and should be routine, unless there are com-
pelling reasons not to stratify reporting, which should be 
explained. 
f. Discussion 
It is useful to begin the discussion by briefly summa-
rizing the main findings, and explore possible mechanisms 
or explanations for these findings. Emphasize the new and 
important aspects of your study and put your findings in 
the context of the totality of the relevant evidence. State 
the limitations of your study, and explore the implications 
of your findings for future research and for clinical practice 
or policy. Discuss the influence or association of variables, 
such as sex and/or gender, on your findings, where appropri-
ate, and the limitations of the data. Do not repeat in detail 
data or other information given in other parts of the manu-
script, such as in the Introduction or the Results section. 
Link the conclusions with the goals of the study but 
avoid unqualified statements and conclusions not ade-
quately supported by the data. In particular, distinguish 
between clinical and statistical significance, and avoid mak-
www.icmje.org 
ing statements on economic benefits and costs unless the 
manuscript includes the appropriate economic data and 
analyses. Avoid claiming priority or alluding to work that 
has not been completed. State new hypotheses when war-
ranted, but label them clearly. 
g. References 
i. General Considerations 
Authors should provide direct references to original 
research sources whenever possible. References should not 
be used by authors, editors, or peer reviewers to promote 
self-interests. Although references to review articles can be 
an efficient · way to guide readers to a body of literature, 
review articles do not always reflect original work accu-
rately. On the other hand, extensive lists of references to 
original work on a topic can use excessive space. Fewer 
references to key original papers often serve as well as more 
exhaustive lists, particularly since references can now be 
added to the electronic version of published papers, and 
since electronic literature searching allows readers to re-
trieve published literature efficiently. 
Do not use conference abstracts as references: they can 
be cited in the text, in parentheses, but not as page foot-
notes. References to papers accepted but not yet published 
should be designated as "in press" or "forthcoming." Infor-
mation from manuscripts submitted but not accepted 
should be cited in the text as "unpublished observations" 
with written permission from the source. 
Published articles should reference the unique, persis-
tent identifiers of the datasets employed. 
Avoid citing a "personal communication" unless it 
provides essential information not available from a public 
source, in which case the name of the person and date of 
communication should be cited in parentheses in the text. 
For scientific articles, obtain written permission and con-
firmation of accuracy from the source of a personal com-
munication. 
Some but not all journals check the accuracy of all 
reference citations; thus, citation errors sometimes appear 
in the published version of articles. To minimize such er-
rors, references should be verified using either an electronic 
bibliographic source, such as PubMed, or print copies from 
original sources. Authors are responsible for checking that 
none of the references cite retracted articles except in the 
context of referring to the retraction. For articles published 
in journals indexed in MEDLINE, the ICMJE considers 
PubMed the authoritative source for information about 
retractions. Authors can identify retracted articles in MED-
LINE by searching PubMed for "Retracted publication 
[pt]", where the term "pt" in square brackets stands for 
publication type, or by going directly to the PubMed's list 
of retracted publications (www.ncbi.nlm.nih.gov/pubmed 
?term = retracted +publication+ [pt]). 
References should be numbered consecutively in the 
order in which they are first mentioned in the text. Identify 
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references in text, tables, and legends by Arabic numerals 
in parentheses. 
References cited only in tables or figure legends should 
be numbered in accordance with the sequence established 
by the first identification in the text of the particular table 
or figure. The tides of journals should be abbreviated ac-
cording to the style used for MEDLIN£ (www.ncbi.nlm 
.nih.gov/nlmcatalog/journals). Journals vary on whether 
they ask authors to cite electronic references within paren-
theses in the text or in numbered references following the 
text. Authors should consult with the journal to which they 
plan to submit their work. 
ii. Style and Format 
References should follow the standards summarized in 
the NLM's International Committee of Medical Journal 
Editors (ICMJE) Recommendations for the Conduct, Re-
porting, Editing, and Publication of Scholarly Work in 
Medical Journals: Sample References (www.nlm.nih.gov 
/bsd/uniform_requirements.html) webpage and detailed in 
the NLM's Citing Medicine, 2nd edition (www.ncbi.nlm 
.nih.gov/books/NBK7256/) . These resources are regularly 
updated as new media develop, and currently include guid-
ance for print documents; unpublished material; audio and 
visual media; material on CD-ROM, DVD, or disk; and 
material on the Internet. 
h. Tables 
Tables capture information concisely and display it 
efficiently; they also provide information at any desired 
level of detail and precision. Including data in tables rather 
than text frequently makes it possible to reduce the length 
of the text. 
Prepare tables according to the specific journal's re-
quirements; to avoid errors it is best if tables can be directly 
imported into the journal's publication software. Number 
tables consecutively in the order of their first citation in the 
text and supply a tide for each. Tides in tables should be 
short but self-explanatory, containing information that al-
lows readers to understand the table's content without hav-
ing to go back to the text. Be sure that each table is cited in 
the text. 
Give each column a short or an abbreviated heading. 
Authors should place explanatory matter in footnotes, not 
in the heading. Explain all nonstandard abbreviations in 
footnotes, and use symbols to explain information if 
needed. Symbols may vary from journal to journal (alpha-
bet letter or such symbols as *, t, :j:, §), so check each 
journal's instructions for authors for required practice. 
Identify statistical measures of variations, such as standard 
deviation and standard error of the mean. 
If you use data from another published or unpublished 
source, obtain permission and acknowledge that source 
fully. 
Additional tables containing backup data too extensive 
to publish in print may be appropriate for publication in 
the electronic version of the journal, deposited with an 
archival service, or made available to readers directly by the 
authors. An appropriate statement should be added to the 
text to inform readers that this additional information is 
available and where it is located. Submit such tables for 
consideration with the paper so that they will be available 
to the peer reviewers. 
i. Illustrations (Figures) 
Digital images of manuscript illustrations should be 
submitted in a suitable format for print publication. Most 
submission systems have detailed instructions on the qual-
ity of images and check them after manuscript upload. For 
print submissions, figures should be either professionally 
drawn and photographed, or submitted as photographic-
quality digital prints. 
For radiological and other clinical and diagnostic im-
ages, as well as pictures of pathology specimens or photo-
micrographs, send high-resolution photographic image 
files. Before-and-after images should be taken with the 
same intensity, direction, and color of light. Since blots are 
used as primary evidence in many scientific articles, editors 
may require deposition of the original photographs of blots 
on the journal's website. 
Although some journals redraw figures, many do not. 
Letters, numbers, and symbols on figures should therefore 
be clear and consistent throughout, and large enough to 
remain legible when the figure is reduced for publication. 
Figures should be made as self-explanatory as possible, 
since many will be used directly in slide presentations. 
Tides and detailed explanations belong in the legends-
not on the illustrations themselves. 
Photomicrographs should have internal scale mark-
ers . Symbols, arrows, or letters used in photomicro-
graphs should contrast with the background. Explain the 
internal scale and identify the method of staining in pho-
tomicrographs. 
Figures should be numbered consecutively according 
to the order in which they have been cited in the text. If a 
figure has been published previously, acknowledge the 
original source and submit written permission from the 
copyright holder to reproduce it. Permission is required 
irrespective of authorship or publisher except for docu-
ments in the public domain. 
In the manuscript, legends for illustrations should be 
on a separate page, with Arabic numerals corresponding to 
the illustrations. When symbols, arrows, numbers, or let-
ters are used to identify parts of the illustrations, identify 
and explain each one clearly in the legend. 
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j. Units of Measurement 
Measurements of length, height, weight, and volume 
should be reported in metric units (meter, kilogram, or 
liter) or their decimal multiples. 
Temperatures should be in degrees Celsius. Blood 
pressures should be in millimeters of mercury, unless other 
units are specifically required by the journal. 
Journals vary in the units they use for reporting hema-
tologic, clinical chemistry, and other measurements. Au-
thors must consult the Information for Authors of the par-
ticular journal and should report laboratory information in 
both local and International System of Units (SI). 
Editors may request that authors add alternative or 
non-SI units, since SI units are not universally used. Drug 
concentrations may be reported in either SI or mass units, 
but the alternative should be provided in parentheses 
where appropriate. 
k. Abbreviations and Symbols 
Use only standard abbreviations; use of nonstandard 
abbreviations can be confusing to readers. Avoid abbrevia-
tions in the tide of the manuscript. The spelled-our abbre-
viation followed by the abbreviation in parenthesis should 
be used on first mention unless the abbreviation is a stan-
dard unit of measurement. 
B. Sending the Manuscript to the Journal 
Manuscripts should be accompanied by a cover letter 
or a completed journal submission form, which should in-
clude the following information: 
A full statement to the editor about all submissions and 
previous reports that might be regarded as redundant publica-
tion of the same or very similar work. Any such work should 
be referred to specifically and referenced in the new paper. 
Copies of such material should be included with the sub-
mitted paper to help the editor address the situation. See 
also Section III.D.2. 
A statement of financial or other relationships that might 
lead to a conflict of interest, if that information is not included 
in the manuscript itself or in an authors'form. See also Sec-
tion II.B. 
www.icmje.org 
A statement on authorship. Journals that do not use 
contribution declarations for all authors may require 
that the submission letter includes a statement that the 
manuscript has been read and approved by all the au-
thors, that the requirements for authorship as stated 
earlier in this document have been met, and that each au-
thor believes that the manuscript represents honest work if 
that information is not provided in another form See also 
Section II.A. 
Contact information for the author responsible for 
communicating with other authors about revisions and fi-
nal approval of the proofa, if that information is not in-
cluded in the manuscript itself. 
The letter or form should inform editors if concerns 
have been raised (e.g., via institutional and/or regulatory 
bodies) regarding the conduct of the research or if correc-
tive action has been recommended. The letter or form 
should give any additional information that may be helpful 
to the editor, such as the type or format of article in the 
particular journal that the manuscript represents. If the 
manuscript has been submitted previously to another jour-
nal, it is helpful to include the previous editor's and review-
ers' comments with the submitted manuscript, along with 
the authors' responses to those comments. Editors encour-
age authors to submit these previous communications. Do-
ing so may expedite the review process and encourages 
transparency and sharing of expertise. 
Many journals provide a presubmission checklist to 
help the author ensure that all the components of the sub-
mission have been included. Some journals also require 
that authors complete checklists for reports of certain study 
types (e.g., the CONSORT checklist for reports of ran-
domized controlled trials). Authors should look to see 
if the journal uses such checklists, and send them with the 
manuscript if they are requested. 
The manuscript must be accompanied by permission to 
reproduce previously published material, use previously pub-
lished illustrations, report information about identifiable per-
sons, or to acknowledge people for their contributions. 
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